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Cancer of the cervix is the second most common cancer for women worldwide, with a 
higher prevalence in developing countries. In Singapore, cervical cancer is the fifth 
most common cancer in females. The objective of this study is to employ gene 
expression profiling of cervical cancer to identify novel differentially regulated genes 
which may serve as molecular diagnostic markers in cervical cancer, and to 
characterize their role in cervical carcinogenesis. We constructed two reciprocal 
(forward and reverse) subtracted cDNA libraries from tumourous and non-tumourous 
cervical tissue taken from a single patient, and 1920 clones obtained from these 
libraries were used to generate cDNA microarrays which were then employed in the 
study of patient samples. A total of 30 tumour samples, 20 non-tumourous tissues of 
the same patient and 12 normal cervical tissues from non-cancerous patients were 
employed in our gene expression studies. Amongst the differentially expressed 
genes, we focused on the study of p16INK4A  (p16) and N-myc downstream regulated 
gene 1 (NDRG1) as these two genes showed the most significant up-regulation in 
cervical cancer tissues compared to non-cancerous and normal cervical tissues. This 
current work focuses on elucidating the functional roles of p16 and NDRG1 in 
cervical cancer and our findings suggest that p16 and NDRG1 are able to mediate 
apoptosis and cell cycle arrest respectively via p53-associated pathways. 
 
Although p16 has been reported to be up-regulated in cervical cancer, its functional 
role in cervical carcinogenesis is not well characterized. p16 is a bona fide tumour 
suppressor gene involved in cell cycle regulation, and it is frequently inactivated in 
other human cancers. Interestingly, over-expression of p16 in cervical cancer is 
seemingly functionally redundant, thus we explored the possible role of p16 up-
regulation in cervical carcinogenesis. We observed that siRNA-mediated silencing of 
p16 augments DNA damage-induced of apoptosis, and furthermore our results 
 viii
suggest that the induction of apoptosis is through p53-mediated intrinsic and extrinsic 
apoptotic pathways. Overall, our findings indicate that high levels of p16 in cervical 
cancer cells confer apoptotic resistance to DNA damage stress including UV-
irradiation and cisplatin treatment, and this shows that p16 up-regulation in cervical 
cancer plays an important role in cervical carcinogenesis by preventing DNA 
damage-induced apoptosis. 
 
Unlike p16, the NDRG1 gene has not been previously implicated in cervical cancer 
and its role in cervical carcinogenesis is unknown. Our studies show that upon 
siRNA-mediated silencing of NDRG1 gene, cervical cancer cells undergo G1 cell 
cycle arrest and eventually enter a senescent-like state whereby they stop 
proliferating. Further investigations revealed that the senescence-like phenotype 
induced by NDRG1 silencing is mediated by the p53 pathway and is irreversible upon 
onset of a senescence-like phenotype. Our data reveal for the first time that NDRG1 
is highly up-regulated in cervical cancer compared to non-tumourous and normal 
cervical tissues, which contributes to evasion of senescence-like phenotype in 
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Section 1 – Introduction and Literature Review 
1.1 The cervix 
The cervix is the lower portion of the uterus (or womb) which connects the body of 
the uterus to the vagina. It measures 3 to 4 cm in length and 2.5 cm in diameter; 
however, this varies according to a woman’s age and hormonal status. The cervix is 
approximately divided into two sections. First, the part of the cervix which extends 
into the body of the uterus is known as the endocervix, or cervical canal, and its 
surface is made up of columnar or glandular epithelial cells which are responsible for 
excreting mucous (Figure 1-1).  











Figure 1-1. Anatomy of the uterine cervix. The cervix is the lower part of the uterus or 
womb. The endocervix, or cervical canal is made up of mucous-secreting glandular epithelial 





The second part of the cervix which extends into the vagina is known as the 
ectocervix and is made up of squamous epithelial cells (Figure 1-1). The junction 
between the endo- and ectocervix is known as the squamocolumnar junction and the 
exact location varies throughout the female reproductive years as it is influenced by 
age and hormonal status. This is partly due to growth and development of the female 
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reproductive organs from the onset of puberty, when hormonal changes occur. The 
squamocolumnar junction shifts due to a process called squamous metaplasia, when 
the columnar epithelium is replaced by newly formed squamous epithelium. The 
anatomical area between the ‘original’ squamocolumnar junction and the ‘new’ 
squamocolumnar junction is known as the transformation zone (Figure 1-2). The vast 
majority of cervical dysplasia and neoplasia originate from this transformation zone, 
where proliferating cells are exposed at the squamocolumnar junction (1), hence it is 
an area of utmost importance during clinical cervical examination. 
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           © 1999 Elsevier 
 
Figure 1-2. Development of the cervical transformation zone. The location of the 
squamocolumnar junction where the endocervix and ectocervix meet is variable throughout 
reproductive years and also shifts due to squamous metaplasia, The anatomical area 
between the ‘original’ squamocolumnar junction and the ‘new’ squamocolumnar junction is 
known as the transformation zone. 
 
 
1.2 Carcinoma of the cervix 
1.2.1 Symptoms and Diagnosis 
Cervical precancers and early cancers do not usually show any symptoms or signs. 
However, when the cancer becomes invasive, one or more of the following 
symptoms may occur: intermenstrual bleeding, postcoital bleeding, heavier menstrual 
flows, excessive or foul smelling discharge, recurrent cystitis, urinary frequency and 
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urgency, backache, and lower abdominal pain. However, these symptoms may also 
be caused by conditions other than cervical cancer, and proper clinical examination 
is required to obtain a conclusive diagnosis. Cervical precancers are most commonly 
detected by microscopic examination of cervical cells in a cytology smear stained by 
the Papanicolaou technique (2). If Pap smear test results show cervical cells with 
precancerous or dysplastic changes, further colposcopic examination of the cervix 
and histopathological examination of cervical biopsies are performed to diagnose the 
presence of cervical intraepithelial neoplasia (CIN).  
 
1.2.2 Cervical dysplasia 
 1.2.2.1 Precancerous squamous cell cervical cancer  
The majority of cervical cancers are preceded by precancerous lesions. These 
precancerous lesions may persist in a non-invasive stage for as long as 20 years, 
with abnormal cytologic profiles, and may either spontaneously regress or progress 
to cancer (3). The precancerous stages of invasive squamous cell cervical carcinoma 
develop from squamous cells in the transformation zone of the squamocolumnar 
junction, and are defined as different grades of dysplasia, or cervical intraepithelial 
neoplasia (CIN). Mild dysplasia is categorized as CIN 1, moderate dysplasia as CIN 
2 and severe dysplasia or carcinoma in situ as CIN 3 (4). Alternatively, under the 
Bethesda system terminology, CIN 1 corresponds to low-grade squamous 
intraepithelial lesion (LGSIL), and CIN 2 and CIN 3 correspond to high-grade 
squamous intraepithelial lesion (HGSIL) (5). CIN 1, 2 and 3 are histopathologically 
categorized based on the proportion of the thickness of the epithelium showing 
dysplastic cells. In CIN 1, dysplastic cells are confined to the surface of the cervix. 
CIN 2 and CIN 3 reveal a greater proportion of the thickness of the epithelium 
composed of dysplastic cells. Most CIN 1 and CIN 2 will spontaneously regress 
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without treatment; approximately 11% of CIN 1 and 20% of CIN 2 will progress to 
CIN 3. CIN 3 or carcinoma in situ has a higher probability of approximately 50% of 
progressing to invasive cancer (6, 7). Longitudinal studies have shown that 30% to 
70% of untreated patients with carcinoma in situ will develop invasive carcinoma over 
a period of 10 to 12 years. However, in about 10% of patients, carcinoma in situ can 
progress to invasive cancer in a period of less than one year (8, 9). 
 
 1.2.2.2 Precancerous cervical adenocarcinoma 
The precancerous lesion of cervical adenocarcinoma is known as adenocarcinoma in 
situ (AIS), and majority of AIS arises from columnar cells in the transformation zone 
of the cervix. AIS is associated with CIN in one to two-thirds of cases (10). Unlike 
squamous cell carcinoma, adenocarcinoma does not have an extended 
precancerous phase.  
 
1.2.3. Invasive cervical cancer 
Invasive cervical cancer begins when the precancerous dysplastic cells penetrate the 
basement membrane and invade the cervical stroma (11). Approximately 90% of all 
cervical cancers are squamous cell carcinomas, with the remaining 10% comprising 
adenocarcinomas and other rare histologic types such as adenosquamous, 
undifferentiated or clear cell carcinomas (3).  
 
The majority of squamous cell carcinomas appear as irregular bands of squamous 
cells with intervening stroma, displaying a large variation in growth pattern, cell type 
and degree of differentiation. The cervical stroma separating the bands of malignant 
cells is infiltrated by lymphocytes and plasma cells and the malignant cells are 
composed of keratinizing and non-keratinizing squamous cells. Cervical tumours may 
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be well, moderately or poorly differentiated carcinomas and approximately 50-60% 
are moderately differentiated cancers while the remainder is evenly distributed 
between the well and poorly differentiated categories. Other rare types of squamous 
cell carcinoma include condylomatous squamous cell carcinoma, papillary squamous 
cell carcinoma, lymphoepithelioma-like carcinoma, and squamo-transitional cell 
carcinoma.  
 
The most common form of adenocarcinoma is the endocervical cell type, where the 
abnormal glands are of various shapes and sizes with budding and branching. Most 
of these tumours are well to moderately differentiated. The glandular elements are 
arranged in a complex pattern. Other forms of adenocarcinoma include intestinal-
type, signet-ring cell adenocarcinoma, adenoma malignum, villoglandular papillary 
adenocarcinoma, endometroid adenocarcinoma and papillary serous 
adenocarcinoma. 
 
Invasive cervical cancer manifests in three morphologically distinct patterns: 
exophytic (or fungating), ulcerating and infiltrative cancer (3), with exophytic tumours 
being the most common, producing a neoplastic mass which projects above 
surrounding mucosa (3). In addition to local invasion, carcinoma of the cervix can 
spread via the regional lymphatics or bloodstream. Staging for cervical cancer is 
based on classifications by the International Federation of Obstetrics and 
Gynaecology (FIGO) and is summarized in Table 1-1 (12). Briefly, Stage 0 is 
carcinoma in situ. Stage 1 is carcinoma strictly confined to the cervix, with measured 
minimum stromal invasion. Stage 2 carcinoma extends beyond the cervix, up to the 
upper two-thirds of the vagina but does extend not into the pelvic wall. Stage 3 
carcinoma extends into the pelvic wall and there is no cancer-free space beween the 
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tumour and pelvic sidewall upon rectal examination. The tumour also involves the 
lower third of the vagina. Stage 4 is carcinoma that has extended beyond the true 
pelvis or has clinically involved mucosa of the bladder and/or rectum and spread to 
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 Table 1-1. Staging of cervical cancer according to FIGO. 
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Figure 1-3. Diagram of extent of spread in FIGO staging of cervical cancer. Stage I to 
IVA invasive cancer and extent of cancer spread represented by grey shaded areas.  
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1.2.4 Epidemiology of cervical cancer: Prevalence, Incidence and Mortality 
 
Cervical cancer is the second most common cancer among women worldwide (13, 
14) and is the fifth most common cancer in females in Singapore, after breast, colo-
rectum, lung and ovarian cancer (15). Although cervical cancer may occur at any age 
beginning from 20 years of age or after the onset of sexual activity (3), the peak 
incidence occurs at 40-45 years of age for invasive cancer and 30 years of age for 
high-grade precancers (3). Older women account for approximately 10% of patients 
with cervical cancer, and are more likely to present with advanced stage disease at 
diagnosis. Cervical cancer is much more common in developing countries, where 
78% of all cases occur, and accounts for 15% of female cancers with a 3% lifetime 
risk. In developed countries, cervical cancer accounts for 4% of new cancers, with a 
lifetime risk of 1% (16), and the incident rates are generally much lower than in 
developing countries, where the highest incidence rates are observed in Latin 
America, the Caribbean, sub-Saharan Africa and Southern and Southeast Asia (16). 
In Singapore, cervical cancer incidence is higher than most of Europe and USA, and 
lower than parts of Asia, Africa and Latin America (15). This marked difference in the 
prevalence and incidence of cervical cancer in developed and developing countries is 
due to the availability of screening (Pap smear) programs. However, mortality rates 
are much lower than incidence rates worldwide. In low-risk regions the survival rate is 
60 to 70%, and even in developing countries, the average survival rate is 47%. 
Overall, cervical cancer incidence and mortality have declined substantially in recent 
years, and is one of the most preventable and curable malignancies, due to the 
introduction of well-developed screening programs which successfully detect early 
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1.2.5 Etiology of cervical cancer 
 1.2.5.1 Human papillomavirus infection 
Human papillomavirus (HPV) infection is the primary risk factor for cervical cancer, 
and is considered the main causative agent for cervical cancer and its precancerous 
lesions. More than a hundred types of HPVs have been identified and characterized 
according to DNA sequence homology, with over 40 types infecting the genital tract 
(18-20). The classification of HPV types is of medical importance, because different 
HPV types induce type-specific lesions, for instance those arising in cutaneous or 
mucoscal epithelia, or those giving rise to benign warts or malignant carcinomas (20). 
 
Genital HPV infection is a relatively common sexually-transmitted infection which is 
frequently detected among young women who are sexually active (21, 22). However, 
not all infected individuals will develop cervical cancer – 80% of HPV infections are 
transient and can be cleared by an effective immune system, whilst the remaining 
20% will persist to cervical dysplasia (22). This is partially explained by the fact that 
infection by low-risk and high-risk HPV types conveys differential cervical cancer risk 
(23, 24). Low-risk HPV types are the major cause of skin and genital warts, while 
infection with oncogenic or high-risk HPV types is associated with development of 
invasive cervical cancer (14, 25). Infection with multiple HPV types is common in low-
grade lesions such as CIN 1, and persistent infection with HPV is necessary for 
malignant transformation. Table 1-2  summarizes the different HPV types and their 
risk classifications (24). HPV 16 is the most common type to be identified in cervical 
cancer cases (18), and HPV 18, 31 and 45 are also consistently associated with 
invasive cervical cancer (19, 26). Worldwide, HPV 16 and 18 are the cause of 54% 








Table 1-2 – Classification of HPV types by cervical oncogenicity. 15 HPV types have 
been classified as high-risk for development of cervical cancer, 3 have been classified as 
probable high-risk, and 12 are classified as low risk, with 3 other types with undetermined risk 





HPV infection, as measured by HPV DNA detection, is found in nearly 100% of 
cervical cancers. HPV infection is initiated when the virus gains entry to the basal 
cells of the epithelium. Minor trauma to the cells, such as during sexual intercourse, 
causes small abrasion in the tissue and allows the virus to gain access to target cells 
at or near the cervical transformation zone. HPV infection first begins in the basal cell 
layer, then infected cells migrate into the suprabasal differentiating cell layers and 
viral replication then takes place in the differentiating keratinocytes (27). For the 
production of infectious virions, HPVs amplify their viral genomes and package them 
into infectious particles which are released from the surface epithelium. Amplification 
of the viral genome may result in 20 to 100 copies of viral DNA per cell, and this 
average copy number is maintained in the undifferentiated basal cells throughout the 
course of the infection (27). This process is illustrated in Figure 1-4 below. 
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Figure 1-4. The human papillomavirus life cycle. HPV infection first begins in the basal 
cell layer, then infected cells migrate into the suprabasal differentiating cell layers 
and viral replication then takes place in the differentiating keratinocytes (28). © 2002 
Nature Publishing Group 
 
 
HPVs are non-enveloped viruses with icosahedral capsids that replicate their 
genome within the nuclei of infected host cells (29). The HPV virion consists of a 
double-stranded, circular DNA genome of approximately 8kb and is organized into 
three major regions, namely, an upstream non-coding region, and two downstream 
protein-encoding regions, the early (E) and late (L) regions. The early region consists 
of six open reading frames (ORFs), E1, E2, E4, E5, E6 and E7, while the late region 
consists of two ORFs, L1 and L2 (30). E6 and E7 encode for viral oncoproteins which 
are critical for viral replication and host cell immortalization, and in oncogenic HPV 
types, for cellular transformation (31). E1 and E2 encode for proteins which are also 
essential for viral replication, while L1 and L2 encode for the viral capsid proteins (32). 
HPV infection involves the coordinated expression of early viral proteins in the lower 
epithelial cell layers, with late genes subsequent being expressed as viral replication 
takes place, leading to changes in the cells such as koilocytosis, nuclear 
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enlargement, multinucleation, dyskeratosis and in some cases, squamous 
intraepithelial neoplasia or CIN.  
 
The entry of HPVs into cervical host cells is followed by three possible events. Firstly, 
the viral DNA is maintained as an extrachromosomal episome, thereby establishing a 
latent infection. Secondly, the conversion of latent infection into a productive one is 
associated with the assembly of infective virions, and thirdly, viral DNA may be 
directly integrated into the host genome (33). In low-grade infections such as CIN 1, 
high-risk HPV genomes are present as episomes, while during progression to high-
grade lesions such as CIN 2 and 3, or carcinomas, the viral genome is often found to 
be integrated into host sequences (27, 34). This integration usually occurs within the 
E2 ORF and hence results in loss of E2 expression. Since E2 is a negative repressor 
of the E6/E7 promoter, disruption of E2 expression leads to higher levels of E6 and 
E7 expression (35-37), which are both crucial for malignant transformation of cervical 
cancer cells. It has been suggested that dysregulation of high-risk HPV E6 and E7 
viral oncoproteins is a key event in the progression of precancerous lesions to high-
grade neoplasia, which leads to increased cell proliferation in the lower epithelial 
layers (38, 39). The frequency of HPV genome integration into the host chromosome 
correlates with lesion grade, from rare in CIN 1 to common in CIN 3, and 
consequently viral integration can be found in almost all cervical carcinomas (40). 
Hence, persistence of HPV infection is an important risk factor in the development of 
CIN and subsequently, invasive cervical cancer (41). 
 
 1.2.5.2 Risk factors in cervical cancer 
Several risk factors for cervical cancer have been identified, including sexual 
intercourse at an early age, multiple male sexual partners, and male sexual partners 
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who themselves have had multiple sexual partners. These factors are associated 
with sexual behaviour mainly due to the fact that the main etiological agent in cervical 
cancer, HPV infection, is sexually transmitted. Other risk factors include the 
prolonged use of oral contraceptives, and smoking. It has also been suggested that 
immunosuppressed and HIV-positive individuals are at a high risk of both HPV 
infection and HPV-associated disease. Herpes simplex virus (HSV) and C. 
trachomatis infection are also associated with cervical cancer. Low socioeconomic 
status has also been implicated as a risk factor due to deficient nutrition, concurrent 
genital infections, and a lack of access to cervical cancer screening programs (19, 42, 
43).  
 
1.2.6 Treatment and prognosis of cervical cancer 
Not surprisingly, infection with high-risk HPVs confers resistance to apoptotic stimuli, 
and clinical studies have shown that HPV-positive cervical tumours exhibit increased 
resistance to treatment and are more clinically aggressive (23, 44-47). The prognosis 
for cervical cancer patients is dependent on stage of disease at time of diagnosis 
(48). Treatment of cervical cancer is affected by stage of the disease, which is based 
on clinical evaluation. The patient’s age, overall physical condition and reproductive 
status are also taken into consideration. For carcinoma in situ, methods of treatment 
include loop electrosurgical excision procedure (LEEP), laser therapy and 
cryotherapy, which are outpatient treatments, or conization, a surgical procedure 
involving resection of a conical area of cervical tissue (42). Patients with invasive 
cervical cancer (FIGO Stage 1A to 4B) are typically treated with one or more of the 
following: simple or radical hysterectomy, radiation therapy, chemotherapy or 
chemoradiation therapy (42, 49). However, tumour resistance to chemoradiotherapy 
in advanced stage disease is still unresolved (50). Poor outcome of treatment in 
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advanced cervical cancer has been shown to be associated with poor tumour 
oxygenation or hypoxia, and this may be the cause of radiation resistance as well as 
tumour recurrence and metastasis (51, 52). Hence, despite the decline in cervical 
cancer incidence and mortality as a result of improved screening programs, there is 
still room for improvement in the treatment of advanced cervical tumours (53).  
 
1.2.7. Prevention of cervical cancer 
Cervical cancer is a preventable disease as there is a long latency period between 
the first appearance of precancerous lesions and progression to invasive cancer. The 
establishment of well-developed population screening programs enables detection of 
pre-invasive disease and early-stage cervical cancer, both of which carry a good 
prognosis. However, despite advances and improvements in cervical cancer 
screening programs, the cancer mortality rate remains high (53), hence there is still a 
need for prevention in cervical cancer. Recent advancements in cervical cancer 
prevention have led to the development of HPV prophylactic vaccines which contain 
virus-like particles (VLPs) that are able to induce virion-neutralizing antibodies upon 
injection into the recipient (54). Gardasil, which is marketed by Merck, contains VLPs 
from HPV types 6, 11, 16 and 18 whereas Cervarix, marketed by GlaxoSmithKline, 
contains VLPs from HPV types 16 and 18. Clinical trials have shown that these 
vaccines are 100% effective in short-term prevention of persistent cervical HPV 
infection and resulting cervical dysplasia. Since cervical cancer is primarily caused by 
oncogenic HPV infection, these vaccines have great potential for eradicating 
precancerous cervical lesions and reducing cervical cancer mortality (54). 
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1.3 Molecular pathogenesis of cervical cancer 
 
1.3.1 HPV E6 and E7 viral oncoproteins dysregulate tumour suppressor 
pathways 
Although epidemiologic data clearly indicate that HPVs are the main etiologic factor 
for cervical cancer, the long latency period between initial HPV infection and 
subsequent cancer development indicates that additional factors and cellular events 
such as genetic aberrations are required for cervical carcinogenesis. It has been 
extensively reported that integration of oncogenic HPV viral genes into the host 
genome and subsequent high expression of the E6 and E7 viral oncoproteins lead to 
genetic instability and alterations in the host cell (35, 38, 55). Hence, both high-risk 
HPV E6 and E7 are needed for induction as well as maintenance of a transformed 
phenotype, particularly by interference with cell cycle control and apoptosis.  
 
High-risk HPV E6 exerts its effects through interaction with p53. E6 complexes with 
the tumour suppressor p53 via a cellular protein, E6-associating protein (E6-AP), 
which results in rapid ubiquitination of p53 and subsequent degradation by the 26S 
proteosome (55-58). E6 has also been reported to indirectly down-regulate p53 
through association with p300/CBP, which is a transcriptional co-activator of p53 (59, 
60). p53 is a well-characterized tumour suppressor that regulates cell cycle 
progression at the G1/S and G2/M checkpoints, namely by triggering cell cycle arrest, 
senescence or apoptosis in response to DNA damage or other cellular and genotoxic 
stress stimuli, and the disruption of p53 function by E6 prevents cells from 
undergoing cell cycle arrest and apoptosis, hence resulting in chromosomal and 
centrosomal instability and enhancing the malignant phenotype (61-63). The E6 
oncoprotein also interacts with a number of other important cellular proteins such as 
the telomerase subunit hTERT, the scaffold protein PDZ, paxillin, Bak, McM7, and 
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interferon regulatory factor 3 (IRF-3), the implications of which are still not fully 
investigated and understood (64-67). 
 
The HPV E7 oncoprotein is also important for both immortalization and viral 
pathogenesis, and exerts its effects mainly through interaction with the 
retinoblastoma (Rb) tumour suppressor protein and its family members p107 and 
p130 (68, 69). In a similar manner to E6, E7 interferes with cell cycle control by 
binding and degrading Rb proteins, which are responsible for regulating G1/S cell 
cycle progression (70). When hypo-phosphorylated, Rb proteins form a complex with 
the E2F family of transcription factors, preventing E2F-dependent transcription of S-
phase genes which drives the cell cycle. Phosphorylation of Rb effectively prevents 
Rb-E2F complex formation, thereby allowing constitutive expression of S-phase 
genes and unchecked cell cycle progression. In short, Rb limits cell proliferation by 
preventing entry into the S-phase of the cell cycle. By binding to Rb, E7 mimics the 
phosphorylation of Rb by preventing Rb-E2F complex formation, hence resulting in 
uncontrolled cell proliferation (71-73). In addition to Rb family members, E7 proteins 
also associate with cyclins A and E as well as cyclin-dependent kinase (cdk) 
inhibitors p21 and p27 to abrogate various cell cycle regulatory mechanisms (69). 
Furthermore, E7 is also able to bypass p53-mediated growth arrest (74-77), thus 
ensuring cell cycle progression even in the presence of growth inhibitory signals. 
 
In this manner, both the E6 and E7 viral oncoproteins contribute to the malignant 
phenotype by binding and degrading the tumor suppressors p53 and RB respectively, 
thereby abolishing two major cell cycle checkpoints and dysregulating two very 
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Figure 1-5. Dual effect of HPV E6 and E7 on the cell cycle E6 and E7 viral oncoproteins 
contribute to the malignant phenotype by binding and degrading the tumor 
suppressors p53 and RB respectively, abolishing and dysregulating two major 
tumour suppressor pathways normally present in cells (78).  
 
 
1.3.2 Chromosomal and genetic alterations 
Chromosomal instability develops at early stages of cervical neoplasia and is 
detectable even in precancerous lesions (79-81). The integration of high-risk HPV 
DNA into the host cell and subsequent expression of E6 and E7 oncoproteins 
induces genomic instability including mitotic defects and aneuploidy in epithelial cells 
and keratinocytes (82-84). Chromosomal alterations have been observed in 95% of 
cervical cancers, with aberrations in chromosome 1 being the most commonly 
reported, namely in the form of deletions and translocations in the 1p11-p13 and 
1q21-q32 regions (85, 86). Translocations between chromosome 1 and other 
chromosomes have also been frequently detected, with the most common “partner” 
chromosome being chromosome 3 (87). However, chromosomal alterations are not 
confined to chromosome 1; allelotyping showed allelic loss in chromosome 5p15 in 
56% of invasive cancers and 21% of precursor lesions (88). Alterations on 
chromosomes 4, 5, 6, 11, 13, 17, 18 and 21 have also been documented. Loss of 
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heterozygosity (LOH) in invasive cervical cancers has also been reported, 
predominantly on chromosomes 3, 5, 11 and less frequently on chromosomes 1, 4, 6, 
10, 17,18 and X (87). Some studies have reported c-myc oncogene amplification and 
over-expression in cervical cancer (89), as well as deletions and mutations in the c-
H-ras oncogene (90), but it has yet to be determined if these alterations have 
significant impact on cervical carcinogenesis. 
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1.4 Diagnostic markers: p16INK4A as a potential biomarker in cervical cancer 
 
1.4.1 p16 is a cell cycle inhibitor that regulates Rb 
p16 was first cloned by yeast-two-hybrid assay from a cDNA library derived from 
Hela cervical cancer cells, and it was discovered to bind directly to cdk4 (91). The 
p16 gene locus on human chromosome 9p21 also encodes a different protein, 
p14ARF (or p19ARF in mouse), arising from an alternate reading frame, with 
independent functions to p16 (Figure 1-7) (92). p16 is a cell cycle regulatory protein 
whose role is to inhibit cyclin-dependent kinases CDK4 and CDK6, and prevent their 
complexing with cyclin D family members, which in turn phosphorylate Rb proteins 
during the G1/S phase of the cell cycle. Phosphorylation of Rb promotes release of 
E2F from the Rb-E2F complex and this drives the cell cycle (91). Hence, p16 
regulates Rb activity, and is responsible for maintaining Rb in an anti-proliferative 
state. Consequently, the p16/Rb pathway is a crucial one in cell cycle regulation, and 
it is frequently abrogated in human cancers through inactivation of the p16 gene.  
 
 
Figure 1-6. Alternative transcripts from the p16 gene locus. The exons of this locus are 
shown as boxes and identified as 1α, 1β, 2 and 3. Alternative splicing generates two different 
transcripts, INK4A (p16) and ARF (p14ARF). Size and composition of respective human and 
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1.4.2 The role of p16 as a tumour suppressor gene 
The expression of p16 is low or undetectable in primary tissues, but its expression is 
regulated in a tissue- and cell cycle-specific manner (93-95). However, p16 mRNA is 
extremely stable and does not fluctuate during cell cycle phases (96). The ability of 
p16 to induce growth arrest when ectopically introduced into cells confirms its role as 
a tumour suppressor gene (97, 98). Ectopic expression of p16 reduces cell 
proliferation in cell culture, and soft agar, and induces G1 cell cycle arrest (92). 
Moreover, loss of p16 in mice was associated with increased incidence of 
spontaneous and carcinogen-induced cancers (99-101). On the molecular level, the 
tumour suppressive activities of p16 are linked to its role as a cell cycle inhibitor and 
its ability to modulate senescence (102, 103). It has been reported that p16 induces 
cell cycle arrest as a protective mechanism against chemotherapy (104). In addition, 
it has also been shown that ras-induced senescence results in the up-regulation of 
p16 expression, and p16-deficient fibroblasts are resistant to ras-induced 
senescence (105). Progressive increase of p16 expression has also been correlated 
with keratinocyte clonal evolution; conversely, inactivation of p16 in primary 
keratinocytes allows the cells to escape replicative senescence (106).  
 
p16 is frequently aberrantly expressed or inactivated by deletion, mutation or 
epigenetic silencing in almost all human cancers, including leukaemia, melanoma, 
liver, lung, bladder, prostate, stomach, oesophageal, breast, colon and brain cancer 
(92, 107). For example, mutations that inactivate the cdk-inhibitory function of p16 
occur in familial melanoma, biliary tract and oesophageal carcinoma, and 
homozygous deletions of the p16 gene locus are found in gliomas, nasopharyngeal 
carcinomas, actue lymphocytic leukaemias, bladder and ovarian cancers. Non-small 
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cell lung carcinomas and head and neck carcinomas have been found to harbour 
both p16 gene deletions as well as mutations. 
 
1.4.3 p16 expression is inversely correlated with Rb expression 
Several studies have shown that p16 expression is inversely correlated with Rb 
expression. It was first observed that p16 levels were high in primary and tumour cell 
lines lacking functional Rb as well as cyclin D-cdk complexes, including 5637 bladder 
cancer cells, MDA-MB468 and BT549 breast cancer cells, and cervical cancer cell 
lines SiHa and Cas Ki, where Rb is inactivated by HPV viral proteins. In contrast, little 
or no p16 was detected in cell lines expressing functional Rb (108). Subsequently, 
Shapiro et al. deduced that there is approximately a hundred-fold difference between 
p16 levels in Rb-positive and Rb-negative cell lines (109). This led to analyses of the 
p16 promoter in order to determine if it is negatively regulated by Rb. Although no 
obvious binding sites were mapped in the p16 promoter, these studies were able to 
show that that there is indeed a feedback loop through which Rb influences and 
represses the transcription of the human p16 gene (96, 110). This resulted in the 
hypothesis that p16 expression peaks at the G1/S transition of the cell cycle after Rb 
phosphorylation is complete and cdk4 activity is no longer required (111), but this has 
not been conclusively confirmed by other studies. Importantly, these findings led to 
the discovery that growth suppression by p16 requires functional Rb protein, and 
when Rb is disabled, the ability of p16 to induce cell cycle arrest is lost (97, 112). 
Hence, excess p16 in Rb-negative cells has no effect on cell cycle progression, and 
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1.4.4 p16/Rb pathway in cervical cancer 
 As discussed previously in Section 1.3.1, phosphorylation of Rb renders it to an 
inactive state. In cervical cancer, the inactivation of Rb is caused by the actions of 
the HPV high-risk E7 oncoproteins, which act downstream of p16/cdk4/cyclin D. It is 
thought that the direct inactivation of Rb by E7 causes the up-regulation of p16 via a 
negative feedback mechanism regulating expression of p16, Rb and E2F (113). 
Growth stimulatory signals lead to activation of G1-phase cyclins and cdks such as 
cdk4/6cyclin D, and this in turn phosphorylates Rb which releases E2F to direct 
transcription of S-phase related genes. E2F accumulation subsequently leads to an 
increase in p16 levels, thereby inhibiting cdk4/6/cyclin D activity, and allowing hypo-
phosphorylated Rb to bind and restrict E2F activity. Consequently, direct inactivation 
of Rb by E7 in HPV-infected cervical cancer cells leads to an accumulation of p16 via 
E2F. p16 itself is a bona fide tumour suppressor which is capable of inducing cell 
cycle arrest mediated by Rb or p53 pathways (92, 114). Interestingly, in cervical 
cancer cells, over-expression of p16 is functionally “inert” and does not exert its 
tumour suppressive functions, thus leading to the postulation that since E7 directly 
inhibits Rb downstream of p16 in the pathway, the over-expression of p16 is 
functionally sequestered and cell cycle progression is unaffected (38). The up-
regulation of p16 is in stark contradiction to its role as a tumour suppressor, and as 
yet, the role of p16 in cervical cancer is unknown, and is generally believed to be 
functionally redundant in cervical cancer.  
 
1.4.5 p16 as a potential diagnostic marker in cervical cancer 
In recent years, several studies have highlighted the use of p16 as a possible 
supplementary marker for disease progression in cervical cancer, due to findings of 
p16 over-expression as detected by immunohistochemical staining, and the 
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observation that p16 expression increased from low-grade CIN lesions to invasive 
carcinoma (115-119). However, these studies have also observed p16-negative CIN 
lesions and carcinomas, and in addition, spontaneous regression of p16-positive 
lesions was also observed, proving that p16 is not an absolute marker for disease or 
progression. Moreover, the use of p16 as a marker in cervical adenocarcinomas and 
its precursors has not been established (120), hence at present, p16 testing is 
regarded as an optional supplementary marker for cervical cancer diagnosis. 
 
In the course of this thesis, we have confirmed the over-expression of p16 in cervical 
cancer tissues compared to non-tumourous and normal cervical tissues, and have 
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1.5 A newly identified up-regulated gene in cervical cancer: N-myc downstream 
regulated gene 1 (NDRG1) 
 
1.5.1 The human NDRG1 gene 
The human NDRG1 gene is also known as Drg-1, Cap43, RTP, PROXY-1 and RIT42, 
as identified by various groups under different physiological conditions (121-125). Its 
official name in the NCBI databases has been designated as NDRG1, and it is 
located on chromosome 8q24, a region that is reportedly amplified in some tumours 
(126). NDRG1 gene is a member of the NDRG family comprising four members 
(NDRG1-4) (127, 128), and it is ubiquitously expressed in most normal human 
tissues (129). The human NDRG1 gene encodes a 3kb mRNA which translates into 
a 43kD protein, and its amino acid sequence encodes three tandem repeats of 
GTRSRSHTSE in the C-terminal region (121, 124, 128). These are not present in 
other NDRG family members, indicating that NDRG1 may have a unique function in 
this family of proteins. The NDRG1 protein sequence does not contain any 
transmembrane domains or signal sequences, however studies have shown that 
NDRG1 protein contains more than seven phosphorylation sites (124, 130). Of these, 
NDRG1 has been identified as a physiological substrate for the serum- and 
glucocorticoid-induced kinase 1 (SGK1),  and phosphorylation of NDRG1 on the 
residues Thr328, Ser330, Thr346, Thr356 and Thr366 primes it for phosphorylation by 
glycogen kinase synthase 3 (GSK3) (131). NDRG1 has been predominantly found in 
the cytoplasm, but its cellular localization appears to be dependent on cell type (129). 
For example, NDRG1 has been associated with the plasma membrane in lactating 
breast and intestinal epithelia, whereas in prostate epithelia, NDRG1 is found in the 
nucleus (129). In kidney proximal tubule cells, NDRG1 has been associated with the 
inner mitochondrial membrane (129). Clearly, NDRG1 expression is cell type-specific, 
and has a number of potential functions. 
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1.5.2 Induction of NDRG1 by various agents 
Although the exact biological function of NDRG1 is unknown, its expression has been 
reported under a variety of conditions. NDRG1 has been implicated in development 
of the kidney, brain and nervous system (132, 133), and its expression is up-
regulated by numerous agents, including nickel, calcium, homocysteine, tunicamycin 
and androgens, in both normal and neoplastic cells (122, 124, 134, 135). NDRG1 
gene expression is also induced by hypoxia conditions, and a variety of hypoxia 
mimetics including cobalt, nickel and desferrioxamine (125, 136), specifically in 
response to induction by the hypoxia inducible factor 1α (HIF-1α) transcription factor 
which is activated under hypoxic conditions (136, 137). In addition to this, the 
promoter region of NDRG1 was found to contain motifs for transcription factors E2F 
and MYC (126, 138). Further analyses revealed that the 5’ end of NDRG1 contains 
many CpG sites, suggesting that NDRG1  may be regulated by DNA methylation 
(139). More recently, some studies have shown that intracellular iron depletion using 
specific iron chelators results in up-regulation of NDRG1 through HIF-1α-dependent 
and independent mechanisms (140). Table 1-3 lists some of the agents known to 
induce NDRG1 in various cell types. 
 
 
© 1999 Elsevier 
 
Table 1-3. Induction of NDRG1 expression in various cell types with different   
treatments. NDRG1 gene expression was found to be upregulated in different cell types 
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1.5.3 NDRG1 plays a role in cell differentiation 
It has also been observed that high expression of NDRG1 is associated with 
keratinocyte differentiation (142), and in agreement with this, NDRG1 was up-
regulated in U937 myelomonocytic cells which had ceased to proliferate, suggesting 
that it was involved in terminal differentiation (141). NDRG1 expression also 
increased in rat peripheral glioma cells which were inhibited from proliferation by a 
cAMP phosphodiesterase inhibitor, isobutylmethyl xanthine (IBMX). Interestingly, this 
was accompanied by a reduction in N-myc, suggesting an inverse correlation 
between N-myc and NDRG1 (126). Also, over-expression of NDRG1 in metastatic 
colon cancer cells reportedly induced morphological changes resembling 
differentiation (139). It was also reported that transcription factors involved in cell 
differentiation, such as PPARγ were able to induce NDRG1 expression (141). Thus, 
there is much evidence pointing to NDRG1 as a differentiation-related gene. 
 
1.5.4. NDRG1 and stress response 
NDRG1 has been linked to stress-response in human umbilical vein endothelial cells 
whereby NDRG1 expression was induced by homocysteine , an agent which induces 
damage in cells, leading to a stress response (124). NDRG1 is also regulated by 
HIF-1, a transcription factor activated under hypoxic conditions (136, 137, 140). 
Under non-hypoxic conditions, the α subunit of HIF-1 is regulated by prolyl 
hydroxylase which allows binding to von HIppel-Lindau (VHL) protein. VHL in turn 
activates ubiquitin ligase E3 to degrade HIF-1α (143). However, when oxygen 
depletion occurs leading to hypoxia, prolyl hydroxylases no longer function, hence 
HIF-1α accumulates in the cell, translocates to the nucleus to bind the HIF-1β subunit, 
and forms the HIF-1 complex that regulates various genes by binding to hypoxia 
response elements (HREs) in their promoter regions (144, 145). NDRG1 has also 
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been shown to be induced by hypoxia in trophoblasts (146). All these observations 
indicate that NDRG1 may have a function in stress response.  
 
1.5.5. NDRG1 and cancer: a putative metastasis suppressor 
NDRG1 has been identified as a metastasis suppressor in some human cancers, 
namely breast, prostate and colon, where NDRG1 expression was reported to be 
significantly diminished (123). Similarly, exogeneous over-expression of NDRG1 
resulted in growth inhibition in colon cancer cells, and suppression of metastasis in 
prostate, colon and breast cancers (139, 147, 148). More recently, it was shown that 
low expression of NDRG1 in pancreatic cancer was associated with poor prognosis, 
and exogenous NDRG1 over-expression markedly decreased tumour growth and 
angiogenesis of pancreatic cancer cells (149). In renal cancer, NDRG1 is reportedly 
down-regulated by the von-Hippel-Lindau (VHL) tumour suppressor gene, which also 
degrades HIF-1α, possibly leading to lower levels of NDRG1 (150, 151). In contrast, 
in a separate study, NDRG1 was found to be up-regulated in human tumours of the 
prostate, lung, breast, kidney, liver and brain (152), possibly due to induction of 
androgens in prostate cancer cells, as well as the hypoxic state of these tumours 
(153). Hence, the role of NDRG1 in cancer is unclear, as some studies have shown 
that it is down-regulated, whilst others report its up-regulation. 
 
1.5.6. NDRG1 and tumour suppressor genes 
 1.5.6.1 NDRG1 and PTEN 
NDRG1 has also been suggested to play a role in tumourigenesis due to studies 
showing the regulation of NDRG1 by various tumour suppressor genes, including 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN), p53 and N-
myc. PTEN over-expression resulted in induction of NDRG1 expression, while PTEN 
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inhibition decreased NDRG1 levels in a time- and dose-dependent fashion (154). As 
PTEN is a tumour suppressor gene that is often down-regulated or inactivated in 
tumour cells and has been implicated as a metastasis suppressor, it is possible that 
the effects of PTEN are partly mediated through NDRG1. In breast and prostate 
cancer, clinical studies revealed almost identical staining patterns for both proteins, 
namely, high expression in normal tissue and low expression in poorly differentiated 
tumour cells. Also, high expression of both NDRG1 and PTEN correlated with better 
survival rates, as opposed to high expression of one or neither of them (154).  
 
1.5.6.2 NDRG1 and p53 
The well-known tumour suppressor p53 has also been reported to regulate NDRG1 
levels in colon cancer cell lines. NDRG1 up-regulation was observed 8 hours after 
p53 induction, suggesting that it is an early target for p53 (155). Knockdown of p53 
using siRNA resulted in a reduction of NDRG1 expression in DLD-1 cells, and a 
luciferase reporter assay revealed that p53 was able to directly target NDRG1. 
Furthermore, studies have shown that NDRG1 expression is induced by DNA 
damage in a p53-dependent manner (123, 155), and both NDRG1 and p53 are 
required for p53-mediated apoptosis. In contradiction to this however, other studies 
have shown a lack of correlation between NDRG1 expression and DNA damage, 
despite p53 up-regulation (140, 148). Also, in the p53-null lung cancer cell line H1299, 
NDRG1 increase was observed in response to iron depletion, thus proving that under 
these conditions NDRG1 induction was not p53-dependent (140). In another study, it 
was shown that NDRG1 inhibits p53 expression and promotes survival in human 
placental trophoblasts in response to hypoxic injury (146). More significantly, p53 
knockout mice do not show a complete loss of NDRG1 expression, confirming that 
there are other mechanisms responsible for regulating NDRG1. Another important 
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observation reported by Okuda et. al. was that in knockout mice lacking NDRG1, no 
tumours developed as a result, thus suggesting that NDRG1 itself is not a classical 
tumour suppressor gene (133). Overall, the relationship between p53 and  NDRG1 is 
still controversial, and is subject to further investigation. 
 
 1.5.6.3 NDRG1 and MYC 
As mentioned earlier, N-myc expression was demonstrated to be inversely correlated 
with NDRG1 (126). N-myc is an important prognostic indicator in neuroblastoma; N-
myc amplification is a predictor of poor clinical outcome. It was demonstrated that 
neuroblastoma cell lines with N-myc amplification exhibited strong repression of 
NDRG1, and a similar effect was noted in a neuroepithelialioma cell line with c-myc 
amplification. Ectopic over-expression of N-myc in neuroblastoma cells without N-
myc amplification resulted in repression of NDRG1, as did induction of c-myc in 
fibroblasts. Furthermore, down-regulation of N-myc resulted in increased NDRG1 
levels in neuroblastoma cells, and re-expression of NDRG1 in neuroepithelioma cells 
with high N-myc expression inhibited the growth of soft agar colonies  (126). In the 
mouse, when N-myc levels were decreased during embryogenesis, Ndr1 (mouse 
homologue) levels increased (138). It was reported that Ndr1 was transcriptionally 
repressed by direct binding of the N-myc/Max heterodimer to the promoter region of 
Ndr. Interestingly, c-myc and c-myc/Max were also able to repress Ndr1 in the same 
manner, thus suggesting that the MYC family may suppress Ndr1. In human NDRG1, 
although c-myc has been proven to bind the NDRG1 promoter via a binding motif 
which is situated close to the initiation site (128), it is unclear whether c-myc or N-
myc bind NDRG1 in the same manner as Ndr1. Nevertheless, there is sufficient 
evidence to state that NDRG1 down-regulation in cells with amplified N-myc likely 
contributes to poor clinical outcome.  
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From the studies conducted above, it is evident that NDRG1 plays an important role 
in cancer, as seen by its interactions with many important tumour suppressor genes. 
 
1.5.7. NDRG1 plays diverse roles in different cell types 
Evidently, NDRG1 is involved in different roles under various physiological and 
biological conditions, and the pathways modulating NDRG1 transcription and 
translation are very diverse. Although various characteristics of NDRG1 have been 
reported by several studies, its exact function is still controversial. The majority of 
studies have indicated that NDRG1 is negatively correlated with cancer, and plays a 
significant role in preventing metastasis and decreasing invasiveness in cancer cells, 
potentially by inducing differentiation. 
 
In our study, using cDNA microarray analysis and real-time PCR, we report for the 
first time that NDRG1 is up-regulated in cervical cancer, and we have sought to 
elucidate its role in cervical carcinogenesis. 
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1.6 Objective and approaches for identifying differentially expressed genes in 
cervical cancer 
Tumourigenesis is a multi-step process, and in cervical cancer this begins with HPV 
infection. Despite advances in cervical cancer screening, the cervical cancer 
mortality rate remains high due to undetected HPV infections which have a long 
latency period. However, HPV infection alone is not sufficient for malignant 
transformation, and other cellular and genetic factors contribute to cervical 
carcinogenesis. Hence, a better understanding of molecular pathways leading to 
cervical dysplasia and neoplasia would help in the identification of surrogate 
biomarkers and aid in diagnosis and treatment of the disease. 
 
The objective of this study was to identify differentially expressed genes in cervical 
cancer that have not been previously reported by other gene expression profiling 
studies, and characterize their role in cervical carcinogenesis. We constructed two 
reciprocal (forward and reverse) subtracted cDNA libraries from tumourous and non-
tumourous cervical tissue taken from a single patient, and 1920 clones obtained from 
these libraries were used to generate cDNA microarrays. A total of 30 tumour 
samples, 20 non-tumourous tissues of the same patient and 12 normal cervical 
tissues from non-cancerous patients were employed in our study. Amongst the 
differentially expressed genes, we focused on the study of p16INK4A  (p16) and N-myc 
downstream regulated gene 1 (NDRG1) as these two genes showed the most 
significant up-regulation in cervical cancer. 
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CHAPTER 2 
Materials and Methods 
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2.4 Buffers  
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2.1 Methods and reagents use 
2.1.1 Cell culture 
SiHa and Cas Ki cervical cancer cell lines were obtained from the American Type 
Culture Collection, and 10 cell lines – A498, A549, Hela, HT-3, K562, MCF-7, HepG2, 
FaDu, DAKIKI and CNE-2 were kindly donated by various labs in the National 
Cancer Centre. All cells were cultured in Dulbecco’s modified Eagle’s medium high 
glucose (DMEM, Sigma) supplemented with 10% heat-inactivated fetal bovine serum 
(Hyclone), 0.1mM non-essential amino acids (Gibco) 2 mM L-glutamine and 1mM 
sodium pyruvate (Sigma) and maintained in a humidified 37oC incubator with 5% CO2. 
Cell lines were routinely checked for mycoplasma by staining with DAPI fluorescent 
dye to detect for cytoplasmic fluorescence. Mycoplasma infections were cleared 
using BM Cyclin reagent (Roche Applied Science). For DNA damage induction, cells 
were subjected to UV irradiation at 100J/m2 using a Stratalinker (Stratagene), or 
treated with 20μM cisplatin (Mayne Pharma Plc, UK). 
 
2.1.2 Tissue specimens  
All cervical cancer tissue samples used in our studies were squamous cell carcinoma 
of the cervix and were obtained from KK Women’s and Children’s Hospital, 
Singapore. All samples were collected with informed consent from patients and were 
immediately frozen in liquid nitrogen upon collection. The total number of samples 
used for our study, and the stage of disease of the samples used, is summarized in 
Table 2-1. Non-tumourous tissue indicates that biopsies were taken from 
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histologically normal tissue adjacent to the tumour. Normal cervical tissue samples 
were obtained from non-cancer, hysterectomy patients. All tumour samples used 
contained HPV type 16 viral DNA and were squamous cell carcinoma of the uterine 
cervix. 
 
Stage 1A/1B Stage 2A Stage 2B Stage 3A/3B
Microarrays 13 8 6 3 20 12
Real time PCR 8 6 - - 14 14




Table 2-1. Cervical tissue specimens collected and corresponding stage of disease 
 
 
2.1.3 Total RNA isolation and quantitation 
RNA was extracted from frozen tissue samples by homogenization (Omni 
International) in 1ml TRIzol reagent (Invitrogen) according to manufacturer’s protocol. 
Briefly, samples in TRIzol were homogenized until no visible tissue debris was visible, 
and vortexed vigorously for 1 minute. Samples were then incubated at room 
temperature for 5 minutes, before centrifugation at 13,000 rpm for 10 minutes at 4oC. 
An additional extraction step was performed with 2:1 phenol (pH 5, Invitrogen) and 
chloroform mixture to eliminate DNA contamination. Centrifugation was performed at 
13,000rpm for 5 minutes at room temperature. RNA was precipitated by mixing the 
aqueous phase with an equal volume of isopropanol, incubation at room temperature 
for 10 minutes and centrifugation at 13,000rpm for 10 minutes at 4oC. The RNA pellet 
was then rinsed with 70% ethanol, air-dried and resuspended in autoclaved ddH2O. 
Total RNA concentration was determined using spectrophotometeric measurement 
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2.1.4 Reverse transcription 
All reagents and reactions were kept on ice where possible. 5μg of total RNA was 
mixed with 2μl of 50ng/μl random hexamer (Invitrogen), 1μl of 500ng/μl oligo-dT12-18 
(Invitrogen) and 9μl of autoclaved ddH2O in a total reaction volume of 12μl and 
incubated at 70oC for 10 minutes before immediately chilling on ice. 1μl of 10mM 
dNTP (Promega), 2μl of 0.1M DTT, 4μl of 5x cDNA synthesis buffer and 1μl 
SuperScript II reverse transcriptase (200U/μl) (Invitrogen) was then added to the 
denatured RNA. The reverse transcription reaction was carried out at 25oC for 10 
minutes, 42oC for 1.5 hours and 80oC for 10 minutes. 1-2μl cDNA was used as 
template for conventional PCR or real-time PCR amplification. 
 
2.1.5 Polymerase chain reaction (PCR) 
Both cDNA or bacteria clones (boiled at 90oC for 5 minutes) were used as templates. 
PCR reactions were performed in 20, 50 or 100μl reaction mixture containing 1x PCR 
reaction buffer, 1.5mM MgCl2, 50μM dNTPs, 0.25μM primer mix and 1-5U of Taq 
polymerase (5U/μl) (Promega). The PCR cycling profile was as follows: initial cycle of 
94oC for 2 minutes, annealing at 50-60oC for 1 minute, extension at 72oC for 2 
minutes, followed by 30 cycles of 94oC for 1 minute, 50-60oC for 1 minute, 72oC for 1 
minute and a final extension step at 72oC for 10 min. The Platinum Pfx proof-reading 
DNA polymerase (2.5U/μl) (Invitrogen) was used for PCR expression cloning. 50μl 
PCR reaction mixture contained template DNA, 1x Pfx amplification buffer, 1x 
enhancer solution, 0.3mM dNTP, 1mM MgSO4, 0.3μM of primer mix and 2.5U of Pfx 
polymerase. The PCR mixture was first denatured at 94oC for 3 minutes, followed by 
30 cycles of denaturation at 94oC for 15 seconds, annealing at 55oC for 30 seconds 
and extension at 68oC for 1 minute per kb and a final extension at 68oC for 8 minutes. 
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2.1.6 Real-time PCR quantitation 
Real-time PCR quantification of gene expression was performed on a RotorGene 
3000 system (Corbett Research, Australia) using QuantiTectTM SYBR Green PCR kit 
(Qiagen). 1-2μl of cDNA was mixed with 2μl of 10μM primer mix, 10μl of 
QuantiTectTM SYBR Green PCR master mix, and ddH2O added to a final volume of 
20μl. The cycle profile of PCR included an initial hot start at 95oC for 15 minutes, 
followed by 40 cycles of 95oC for 15 seconds, 50-60oC for 30 seconds and 72oC for 
30 seconds. All reactions were performed in duplicate. Melting curves for each 
sample were monitored to ensure specificity of amplification. Standard curves for 
each gene were generated independently by preparing 10x serial dilutions of 
template DNA. The relative copy number of each sample was calculated according to 
their standard curves using Rotor-Gene software (v6.0.23). Normalization for each 
sample was performed against 18S rRNA relative copy numbers for the same 
sample. Relative gene expression changes were calculated by adjusting the copy 
number of control samples to a value of 100. 
 
2.1.7 T/A Cloning 
T/A cloning was performed using the pCR2.1-TOPO TA Cloning kit (Invitrogen). PCR 
products amplified using Taq polymerase were directly used in the TOPO cloning 
reactions. 4μl of PCR product was gently added to a mixture of 1μl salt solution and 
1μl of pCR2.1-TOPO vector, incubated for 30 minutes at room temperature and 
chilled on ice. 2μl of the reaction mixture was mixed gently with a vial of One Shot 
Chemical Competent E. coli cells and incubated on ice for 25 minutes. After a heat-
shock step at 42oC for 30 sec, the cells were immediately cooled on ice for 2 minutes, 
and 250μl of SOC media was then added to the cells. After shaking at 200rpm for 60 
minutes at 37oC, 10-50μl of the transformation mixture was spread on a pre-warmed 
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100μg/ml ampicillin-containing LB agar plate with X-gal (50μl of 40mg/ml X-gal (Bio-
Rad) spread on each plate) and incubated overnight at 37oC. For PCR products 
amplified by proofreading Pfx polymerase, two additional steps were added involving 
firstly purification of the PCR product with a PCR purification kit (Qiagen), and 
secondly the addition of ‘A’ nucleotide residues to the 3’ end of the purified PCR 
products. Briefly, 5μl of purified PCR product was incubated in a 10μl reaction 
mixture containing 1x PCR reaction buffer, 1.5mM MgCl2, 50µM dATP, and 0.5U Taq 
polymerase for 10 minutes at 72oC. 4μl of this reaction was then used in the TOPO 
cloning reaction as described above. White or light blue colonies were picked, boiled 
in 100μl ddH2O and used as templates for verification of inserts by PCR using 
universal M13 forward and reverse primers. 
 
2.1.8 Preparation of competent cells (rubidium chloride method) 
A single colony of DH5α cells was inoculated in 5ml of LB broth and cultured 
overnight at 37oC. 1ml of the overnight culture was inoculated into 100ml of LB broth 
and incubated at 37oC with shaking at 250rpm. The growth of bacteria culture was 
monitored using a spectrophotometer. When the absorbance reading at 600nm 
reached 0.48 units (A600 = 0.48), the bacteria culture was kept on ice for 15 minutes 
and centrifuged at 5,000rpm for 5 minutes at 4oC without applying the ‘BRAKE’ mode. 
The bacterial cell pellet was resuspended in 40ml of TfbI buffer and incubated on ice 
for 15 minutes. After centrifugation at 5,000 rpm for 5 minutes at 4oC, the cell pellet 
was then resuspended in 4ml of TfbII buffer. The competent cells were transferred to 
pre-cooled 1.5 ml tubes in 200μl aliquots and snap-frozen in liquid nitrogen before 
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2.1.9 Plasmid sub-cloning 
5μg of pcDNA3 vector (Invitrogen) and 10μg of pCR2.1-TOPO containing the gene of 
interest were independently digested with appropriated restriction enzymes. After gel 
electrophoresis, the desired bands were excised and purified using QIAquick Gel 
Extraction kit (Qiagen). The concentration of eluted DNA fragments was determined 
by gel electrophoresis using a quantitative DNA ladder (Fermentas). For ligation 
reactions, the molar ratio of vector to insert (gene of interest) was at least 1: 5. The 
20μl ligation mixture containing vector, insert, 1x ligation buffer and 1μl T4 DNA 
ligase (New Englad Biolabs) was incubated overnight at 16oC. 10µl of ligation 
reaction mixture was added to 100μl of competent cells, mixed gently by tapping the 
tube, and incubated on ice for 1 hour. After heat shock at 42oC for 45 seconds and 
snap-cooling on ice for 2 minutes, 0.9ml of SOC medium was added and incubated 
at 37oC with shaking at 250rpm for 1 hour. The transformed cells were briefly 
pelleted by centrifugation at 4,000 rpm to remove excess SOC medium, then spread 
onto 50µg/ml ampicillin-containing LB agar plates and incubated overnight at 37oC. 
 
2.1.10 Plasmid isolation 
Plasmids were isolated from 6ml of overnight E.coli cultures in 50µg/ml ampicillin-
containing LB broth using QIAprep Spin Miniprep kit (Qiagen) according to 
manufacturer’s instructions. For large scale of plasmid isolation, a single colony from 
a freshly streaked plate was inoculated in 3ml starter cultures of LB broth and 
incubated for 8 hours at 37oC with vigorous shaking. The starter culture was then 
diluted 1:500 in 1L of selective 50µg/ml ampicillin-containing LB broth and grown at 
37oC for 16 hours with vigorous shaking (~250rpm). Plasmid isolation was then 
performed using the QIAGEN Plasmid Maxi kit (Qiagen) according to manufacturer’s 
instructions. 
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2.1.11 DNA sequencing 
DNA sequencing was performed using ABI PRISM BigDye Terminator v1.1 cycle 
sequencing Ready Reaction kit (Applied Biosystems). 90-100ng of PCR products or 
200-500ng of plasmid DNA in a volume of 4.5µl was mixed with of 4µl of BigDye 
reaction mixture, 1.5µl of 1µM primer and incubated for 25 cycles of 96oC for 10 
seconds, 50oC for 5 seconds and 60oC for 4 minutes. The reaction mixture was 
precipitated with 10µl ddH2O, 2µl of 3M sodium acetate and 50µl absolute ethanol at 
room temperature for 30 minutes and centrifuged at 13,000 rpm for 20 minutes at 
room temperature. The pellet was washed with 125µl 70% alcohol and air-dried 
before resuspending in 15µl of ABI loading solution. Each sample was then 
denatured at 95oC for 5 minutes before analysis on the ABI Prism 377XL automated 
DNA sequencer.  
 
2.1.12 Subtracted cDNA library synthesis  
Using tumourous and non-tumourous cervical tissue taken from a patient with Stage 
1B cervical cancer, two reciprocal subtracted cDNA libraries were constructed 
according to the Clontech PCR-Select cDNA subtraction kit protocol which is 
summarized in a flow-chart diagram (Figure 2-1 below). Briefly, 2µg total RNA from a 
cervical tumour sample (tester) and non-tumourous sample (driver) was used to 
generate first strand cDNA by reverse transcription. Each reaction contained 2μg 
total RNA, 1μM cDNA synthesis primer, 2μl 5x first-strand buffer, 1μM dNTP mix, and 
20U AMV reverse transcriptase made up to a total of 10μl using ddH2O (all reagents 
provided). The reaction was incubated at 42oC for 1.5 hours in a dry incubator. This 
was followed by second-strand cDNA synthesis, after which double-stranded cDNA 
products were purified using phenol/chloroform extraction. Each second-strand 
reaction contained the following: 48.5μl ddH2O, 16μl 5x second strand buffer, 1.6μl 
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dNTP mix (10mM), and 4μl 20x second strand enzyme cocktail. The reaction mix 
was mixed by gentle pipetting and incubated at 16oC for 2 hours in a thermal cycler, 
following which 2μl of T4 DNA polymerase was added and mixed thoroughly. The 
reaction was further incubated at 16oC for 30 minutes. To terminate the reaction, 4μl 
of 20x EDTA/glycogen was added. Phenol/chloroform extraction was performed by 
adding 100μl phenol:chloroform:isoamyl alcohol (25:24:1, Invitrogen) and vortexed 
vigorously before centrifugation for 10 minutes at 13,000rpm in a benchtop centrifuge 
at room temperature. This step was then repeated with 24:1 chloroform:isoamyl 
alcohol before precipitation with 40μl ammonium acetate and 300μl 95% ethanol, 
centrifugation at 13,000rpm, washing the pellet with 80% ethanol and air-drying at 
room temperature. Pellets were re-suspended in 50μl ddH2O. Purified cDNAs were 
then digested with RsaI restriction enzyme to generate shorter cDNA fragments that 
are more suitable for adaptor ligation and subsequent subtraction steps. Each 
digestion reaction contained 43.5μl purified cDNA, 5μl 10x RsaI restriction buffer and 
1.5μl RsaI enzyme (10U/μl) and was incubated at 37oC for 1.5 hours. This was then 
purified by phenol:chloroform extraction as described above. Air-dried pellets were 
re-suspended in 5.5μl ddH2O in preparation for adaptor ligation. Adaptor sequences 
specific for tester cDNA populations were then ligated onto the appropriate cDNA 
populations. Driver cDNA was not ligated with adaptors. Briefly, 2μl RsaI digested 
and purified cDNA was mixed with 2μl of 2 different provided adaptor sequences 
(10μM), 2μl 5x ligation buffer, 1μl T4 DNA Ligase (400U/μl) and 3μl ddH2O and 
incubated at 16oC overnight. 1μl of EDTA/glycogen mix was added to stop the 
ligation reaction, and samples were further heated at 72oC for 5 minutes to inactivate 
the ligase. After a brief centrifugation, 1μl of each tube was removed for subsequent 
checking by gel electrophoresis. Following this, two subtractive hybridization steps 
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between the tester and driver cDNA populations were carried out to enrich for 
differentially expressed sequences in each population. 1.5μl RsaI driver cDNA (not 
ligated to adaptor) was mixed with 1.5μl of each adaptor-ligated tester cDNA 
population from the previous step, and mixed with 1μl of 4x hybridization buffer. Each 
tube was overlaid with a drop of mineral oil, centrifuged briefly and incubated at 98oC 
for 5 minutes, before an 8 hour incubation at 68oC. Maximum time of incubation was 
12 hours. After this, a second round of hybridization was carried out by mixing 
additional 1μl fresh driver cDNA, 1μl 4x hybridization buffer, 2μl ddH2O, denaturation 
at 98oC for 1.5 minutes, and immediately adding to the existing reaction mix from the 
first hybridization step. This reaction was then incubated at 68oC overnight. The final 
step consisted of PCR amplification of subtracted cDNAs, by using 1μl of each 
subtracted sample to 19.5μl ddH2O, 2.5μl 10x PCR reaction buffer, 0.5μl dNTP mix 
(10mM), 1μl PCR primer (10μM) and 0.5μl 50x Advantage cDNA polymerase. 
Cycling parameters were as follows, 94oC for 25 seconds, followed by 27 cycles of 
94oC for 10 seconds, 66 oC for 30 seconds and 72 oC for 1.5 minutes. The resulting 
PCR reaction was diluted by mixing 3μl of product with 27μl ddH2O. 1μl of this diluted 
product was then used in a secondary PCR reaction containing additional 18.5μl 
ddH2O, 2.5μl 10μl 10x PCR buffer, 1μl nested PCR primer 1 (10μM), 1μl nested PCR 
primer 2R (10μM), 0.5μl dNTP mix (10mM) and 0.5μl 50x Advantage cDNA 
polymerase mix. Cycling parameters were as follows, 10 to 12 cycles of 94 oC for 10 
seconds, 68 oC for 30 seconds and 72 oC for 1.5 minutes. 8μl each from the first and 
second PCR reactions were analyzed on a 2% TBE-agarose gel. Successfully 
subtracted samples (as judged by enrichment of products on the gel) were then sub-
cloned into pCR2.1-TOPO TA cloning vectors, transformed into One Shot Chemical 
Competent E. coli cells and plated on ampicillin-containing LB agar plates. Colonies 
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were picked and verified by DNA sequence analysis. Both tester and driver cDNA 
subtracted libraries were amplified by PCR and spotted onto glass slides to generate 
cDNA microarrays as described below.  
 
2.1.13 cDNA microarray fabrication 
A total of 1920 clones were obtained from the forward and reverse subtracted 
libraries, 1108 clones from the forward library (where tumour tissue is used as the 
‘tester’ and the non-tumourous tissue is the ‘driver’) and 812 clones from the reverse 
library (non-tumourous tissue used as ‘tester’, tumourous tissue as the ‘driver’). 
These clones were cultured in 96-well plates, boiled to denature the bacteria and 5μl 
of each was amplified in 100μl PCR reactions. In addition to the library clones, we 
also included the housekeeping genes, β-actin, α-tubulin, GAPDH, beta-2-
microglobulin, ubiquitin, and cyclophilin, and negative-control plant genes, amino-
cyclopropane carboxylate oxidase (ACCO) and flavanone 3-hydroxylase (F3H). 
These 1928 elements were spotted in duplicate on each slide, generating a total of 
3856 spot elements per slide. 5μl PCR product was analyzed in a 2% TBE-agarose 
gel after which the remaining PCR products were purified by isopropanol precipitation, 
resuspended in 15μl 3x SSC and printed in duplicate onto poly-L-lysine (Sigma 
Diagnostics, St. Louis, MO) coated glass slides using a GMS 417 arrayer (Genetic 
Microsystems Inc., Woburn, MA). The diameter of the spotting pin used was 150 μm, 
the distance between each spot on the slide was 300 μm and 48 slides were 
generated per printing run. Each slide was hydrated for 2–3 sec over a steaming 
100°C water-bath, snap-dried for 5 seconds on a 100°C heating block and cross-
linked with 550mJ ultraviolet irradiation using a Stratalinker (Stratagene, La Jolla, 
CA). The slide was then washed for 10 min in 0.2% SDS and rinsed 5x in distilled 
water before being denatured for 5 minutes in 100°C distilled water, desiccated for 5 
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minutes in 95% ethanol and air-dried for 5 min in an 80°C oven. Slides were stored in 
a dry cabinet until hybridization. 
 
                       Figure 2-1. Clontech PCR-Select cDNA subtractive hybridization
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2.1.14 Microarray hybridization 
Fluorescent labelling of cDNAs and microarray hybridization were carried out using 
the Two-step 3DNATM Expression Array Detection kit (Genisphere Inc, Montvale, NJ) 
according to the manufacturer’s instructions with minor modifications. 10μg total RNA 
was used for each 20μl reverse transcription reaction using the Cy5 or Cy3-labelled 
RT primers provided. Test sample cDNA (tumour, non-tumourous or normal cervical 
tissue samples) were labeled with Cy5 fluorescent dye, and reference sample cDNA 
(10 reference cell lines, see Section 2.1.1) was labeled with Cy3 fluorescent dye. 
Briefly, each reaction was incubated at 42oC for 2 h, followed by addition of 3.5μl of 
0.5 M NaOH/50mM EDTA, incubation at 65oC for 10 minutes, neutralization with 5μl 
of 1M Tris-HCl, pH 7.5 and addition of 60μl 3M ammonium acetate.  The Cy3TM 
(reference) and Cy5TM (test sample) cDNA mixture were combined and precipitated 
by mixing with 1μl of COT-1 DNA (GIBCO), 1μl of yeast tRNA (GIBCO) and 1μl of 
oligo-dT blocking reagent (provided) in 450μl of 100% ethanol, and incubated at -
20oC for 30 minutes. The cDNA was resuspended in 3μl of ddH2O and mixed with 
15μl of cDNA hybridization buffer (provided), incubated at 65oC for 5 minutes and 
then applied to the spotted microarray and covered with a glass coverslip. Each slide 
was placed in a humidified ArrayItTM hybridization cassette (TeleChem International, 
Inc., Sunnyvale, CA) and incubated overnight in a 42oC water bath. Slides were then 
washed twice each in 2x SSC/0.1% SDS and 0.2x SSC/0.1% SDS for 10 minutes at 
room temperature. After a final wash with 0.1x SSC, slides were spin-dried and 
hybridized overnight with 2.5μl of Cy3 and Cy5 3DNA capture reagents in 15μl of 
3DNATM hybridization buffer at 65oC in a water bath. The washing steps were carried 
out as mentioned above. After spin-drying, each microarray was scanned using the 
GMS 418 Array Scanner (Genetic microsystems, Wobrun, MA), with independent 
images capture for Cy3 and Cy5 channels. 
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2.1.15 Microarray image data analysis 
Image analysis was performed using using ImaGene 4.0 software (BioDiscovery, LA, 
CA). For each image, spots were defined by positioning a grid of circles around each 
spot. The fluorescent signals were measured as the mean pixel intensity within each 
circumscribed spot and local background for each spot was measured using the 
mean pixel intensity outside the circumscribed spot within a specific square boundary. 
Spots that were contaminated with fluorescent specks or other blemishes, or where 
background values were higher than the spot signal were considered as missing. The 
signal intensities from both Cy3 and Cy5 channels were normalized by applying a 
single scaling factor computed by taking the ratio of the total signal intensities of each 
channel such that the signal intensities of majority of spot elements on each array 
would have a Cy3/Cy5 ratio of 1.0. Spots that gave signals of 1.5-fold or more were 
considered as differentially expressed, and duplicate spots without reproducible 
signals were excluded from final analysis. The resulting signal values were visualized 
using Cluster and Treeview software available from http://rana.lbl.gov/ (M. Eisen, 
University of California, Berkeley). Differentially expressed genes were further 
verified with statistical tests and validated using real-time PCR. 
 
2.1.16 Affymetrix GeneChip® analysis 
All cDNA synthesis, cRNA synthesis and labelling, hybridizations, wash and scan 
steps were performed according to protocols from Affymetrix Inc. (Santa Clara, CA). 
In summary, 5μg total RNA was converted to double-stranded cDNA using a T7-
(dT)24 primer containing T7 RNA polymerase promoter and Superscript II reverse 
transcriptase (Invitrogen). The cDNA was transcribed into biotinylated 
complementary RNA (cRNA) by incorporating biotin-CTP and biotin-UTP using 
GeneChip® IVT Labeling Kit (Affymetrix Inc, Santa Clara, CA). Biotinylated cRNA 
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from each sample was fragmented to obtain sequences of approximately 40–100 
bases, and 10μg of the fragmented cRNA was hybridized to the Affymetrix 
GeneChip® Human Genome U133A 2.0 Array for 16 h at 45°C with constant rotation 
at 60rpm. After washing, the hybridized chips were sequentially stained with 
streptavidin-phycoerythrin (Molecular Probes, Invitrogen), biotinylated goat anti-
streptavidin (Vector Laboratories, Burlingame, CA) and streptavidin-phytoerythrin for 
a second time, for signal amplification. All washes and staining procedures were 
performed on an Affymetrix Fluidics station. Following this, GeneChips® were 
scanned with the Affymetrix GeneArray scanner for fluorescence signal detection. 
Raw expression data were analyzed using Affymetrix Microarray Suite version 5.0 
(MAS5) software. The average intensity for the genes in total was normalized to 500. 
Based on the signal to noise ratio, an absolute expression level (signal intensity) and 
a “present or “absent” call was assigned to each transcript. Probe sets that were 
designated “absent” by the detection algorithm were excluded from analysis. Gene 
annotations were downloaded from Affymetrix NetAffx website and genes of interest 
were matched to their probe sets. Using Affymetrix MAS5 software, probe sets 
representing genes of interest were selected for further analysis. Corresponding 
increases and decreases in signal intensity for each probe set were generated by 
MAS5 change call algorithm, which generates a change p-value and an associated 
change status (Increase-I, Marginal Increase-MI, no change-NC, Decrease-D or 
Marginal Decrease-MD). Further analysis was performed using Spotfire software 
(Spotfire, Inc., MA, USA) and Bibliosphere software (Genomatix, Germany). 
 
2.1.17 Northern blot analysis 
The Clontech human 12-Lane multiple tissue Northern (MTN) blot (Clontech) was 
hybridized with p16, NDRG1 and β-actin probes prepared using purified PCR 
 50
Section 2 – Experimental Procedures 
products (see Section 2.2 for primers), according to protocols recommended by the 
StripEZTM DNA kit (Ambion). Briefly, 25ng of PCR products in 9μl of TE buffer was 
denatured at 100oC for 10 minutes and chilled for 5 minutes on ice before adding to a 
reaction mixture containing 5μl of [α-32P] dATP (10 mCi/ml) (NEN, P/N 
BLU012Z250UC), 2.5μl  of 10x decamer solution, 5μl of 5x buffer, 2.5μl of 10x dCTP 
and 1μl of Klenow and incubated at 37oC for 30 minutes. The labelling reaction was 
stopped with 1μl of 0.5M EDTA. The 32P-labeled probe was then diluted to a total 
volume of 100μl with TE buffer before purifying with mini Quickspin columns (Roche) 
according to manufacturer’s instructions. The Clontech membrane was pre-
hybridized in Pyrex hybridization glass tubes containing Ultrahyb solution (Ambion) at 
42oC for 45 minutes  with rotation in a Hybaid oven. After denaturation at 100oC for 
10 minutes followed by immediate chilling on ice, the purified probe was then added 
into the Ultrahyb solution with the membrane and incubated for 16 hours at 42oC. 
The membrane was then washed in 2x SSC/ 0.05% SDS at room temperature for 30 
minutes, followed by 0.2x SSC/ 0.1% SDS at 65oC for 30 minutes. Detection of signal 
was conducted by autoradiography using Kodak BIOMAX MR film (Eastman Kodak) 
and cassettes with intensifying screens at –80 oC. Images were also captured using 
Phosphor-screens and quantitated using Molecular Imager FX Pro MultiImager 
System (Bio-Rad). Membranes were stripped using the same kit that was used for 
the labelling reaction (StripEZTM DNA kit, Ambion). The hybridized probe was 
removed from the membrane by incubating with 1x Probe Degradation Buffer for 2 
min at RT, then transferring to 68 oC for 10 min. After discarding the Probe 
Degradation Buffer, 1x Blot Reconstitution Buffer in 0.1% of SDS was added and 
incubated for another 10 min at 68 oC. Probe removal was confirmed by monitoring 
radioactivity count with a Geiger counter. 
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2.1.18 siRNA transfection 
Cells were grown directly in 6-well culture plates or on coverslips in 6-well plates and 
transfected with siRNAs targeting the gene of interest using Oligofectamine reagent 
(Invitrogen). 5µl Oligofectamine was incubated with 10µl OptiMEM I reduced serum 
medium (Gibco) for 15 minutes at room temperature in polypropylene 1.5ml 
microtubes. 20-100nM siRNA was diluted in 185µl OptiMEM and incubated with the 
15µl Oligofectamine/OptiMEM mixture for a further 15 minutes at room temperature. 
The siRNA-Oligofectamine complex was then diluted in 800µl OptiMEM and added to 
each well in a final volume of 1ml. For co-transfections, each siRNA sequence was 
complexed separately with the Oligofectamine reagent, before combining the siRNAs 
in a final volume of 1ml OptiMEM per well. Transfection mixture was removed from 
the cells after 4-5 hours and 1.5ml fresh complete DMEM was added to each well. 
 
2.1.19 DNA transfection 
Cells were grown directly in 6-well culture plates or on coverslips in 6-well plates and 
transfected with plasmid constructs containing the gene of interest using 
Lipofectamine reagent (Invitrogen). 6µl PLUS reagent was mixed with 50μl OptiMEM 
reduced serum medium (Gibco) and 2 to 3μg of plasmid construct and incubated for 
15 minutes at room temperature in a polypropylene tube. 6μl Lipofectamine reagent 
was diluted in 50μl OptiMEM and mixed with the DNA-PLUS mixtured for a further 15 
minutes at room temperature. The DNA-Lipofectamine complex was then diluted in 
800µl OptiMEM and added to each well in a final volume of 1ml. Transfection mixture 
was removed from the cells after 4-5 hours and 1.5ml fresh complete DMEM was 




Section 2 – Experimental Procedures 
2.1.20 Preparation of pcDNA3-NDRG1-FLAG plasmid construct 
Full length NDRG1 was PCR-amplified from cDNA reverse-transcribed from total 
RNA derived from the SiHa cervical cancer cell line, using primers specific for 
NDRG1 (Section 2.2). Full length NDRG1 PCR product was diluted 1:1000 and 1μl 
was used to generate NDRG1-FLAG protein using two-step PCR. First, NDRG1-
FLAG product was generated using the full length NDRG1 forward primer, and a 
reverse primer containing the 3’ end of NDRG1 and part of the FLAG sequence 
(Section 2.2). The PCR product was diluted 1:1000 and 1μl was used in the second 
PCR using full length NDRG1 forward primer and reverse primer containing the rest 
of the FLAG sequence, and a stop codon. PCR reactions were performed using Pfx 
polymerase (Section 2.1.5). 
 
2.1.21 Selection of pcDNA3-NDRG1-FLAG stable clones 
SiHa cells were transfected with pcDNA3-NDRG1-FLAG construct according to 
procedures outlined in Section 2.1.19. After 24 hours post-transfection, complete 
DMEM containing 600μg/ml Geneticin (G418, Gibco) was added to transfected cells 
to select for cells containing the gene construct of interest. Optimal concentration of 
Geneticin used for selection was determined prior to transfection by incubating SiHa 
cells with varying concentrations of 200 to 800 μg/ml Geneticin. The concentration at 
which 50% of the cells originally present in culture were non-viable after 4 days was 
selected. Selection of stable clones was performed by changing the medium 
whenever necessary to remove floating cells, and when remaining cells had formed 
colonies visible in the dish without the aid of a microscope. Clones were picked by 
aspirating off all medium from the dish, and gently dislodging the colonies by 
pipetting 15μl media over the colonies using 200μl pipette tips. Each colony was 
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deposited in 24 well plates and gradually cultured until cell numbers increased before 
confirming the stable expression of the construct by Western blot analysis. 
 
2.1.22 Western blot analysis  
Cells were lysed for 15 min on ice in lysis buffer containing 10mM Tris-HCl (pH 7.4), 
150mM NaCl, 1mM EDTA, 1% Triton X-100, 0.5% NP-40 and 1x Complete protease 
inhibitor cocktail (Roche, Germany). Lysates were centrifuged for 15 min at 14,000 
rpm, 4oC and protein concentration was determined by spectrophotometry using Bio-
Rad protein assay reagent. 60μg protein lysate was resolved on 12% SDS-PAGE 
mini-gels and transferred to nitrocellulose membranes (Amersham) using a semi-dry 
transblotting system (Bio-Rad). Blots were developed using Millipore Immobilon 
western chemiluminescent HRP substrate and CL-Xposure film (Pierce). Antibodies 
used were β-actin (A1978, Sigma), p16 (Ab-2 Neomarkers), p14 (Ab-2, Neomarkers), 
Rb, p53, phospho-p53 serine 15, phospho-p53 serine 46, p16, p21 (Cell Signaling 
Technologies), NDRG1 (sc-19464, Santa Cruz) and anti-FLAG (Stratagene). Blots 
were stripped and re-probed several times using Restore stripping buffer (Pierce 
Biotechnology) or stripping buffer containing β-mercaptoethanol and SDS. 
 
2.1.23 Apoptosis assays - FACS analysis and TUNEL assay 
Cells were harvested with 0.25% trypsin/PBS and washed once in PBS before fixing 
in 70% ice-cold ethanol at 4oC overnight. All centrifugation steps were carried out at 
500xg for 5 minutes at 4oC. After fixing, cells were washed once in PBS and 
resuspended in PBS containing a final concentration of 50μg/ml propidium iodide and 
1mg/ml RNase A. Cell cycle populations were analyzed by flow cytometry on a 
FACSCalibur (Becton Dickinson). TUNEL assay (in situ cell death detection kit, 
Roche) was used to detect apoptotic cells. Briefly, cells grown on coverslips were 
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fixed in 3.7% formaldehyde for 15 minutes at room temperature, rinsed once in PBS 
and permeabilized in 0.1% Triton X-100/0.1% sodium citrate for 2 minutes on ice. 
Cells were then incubated in TUNEL reaction mix for 1 hour at 37oC in a dark 
humidified chamber. After rinsing twice in PBS, cells were mounted onto glass slides 
in DAPI-containing mounting medium (Vectashield, Vector Laboratories). Slides were 
then visualized on a LSM-510 laser-scanning confocal microscope (Carl Zeiss). 
 
2.1.24 BrdU cell proliferation assay 
1x106 cells were labeled with 20μM BrdU (BD Pharmingen) in culture medium at for 2 
hours at 37oC in a CO2 incubator. Cells were harvested with 0.25% trypsin/PBS, 
washed once with PBS and fixed in ice-cold 70% ethanol at 4oC overnight. All 
centrifugation steps were carried out at 500xg for 5 minutes at 4oC. After fixing, cells 
were washed once in PBS and thoroughly resuspended in 1ml 2M/HCl/Triton X-100 
for 30 minutes at room temperature. Cells were then pelleted and the supernatant 
aspirated before adding 1ml 0.1M sodium borate at pH 8.5 as a neutralization step. 
The cells were pelleted and washed once in 1% BSA/PBS. 0.5μg/ml anti-BrdU 
antibody was then added in a volume of 100μL and incubated at room temperature 
for 1 hour. Cells were washed once in 1% BSA/PBS and incubated with Alexa Fluor 
488-conjugated goat anti-mouse (Molecular Probes) for 30 minutes on ice before 
washing in 1% BSA/PBS and resuspending in 300μl PBS containing final 
concentrations of 50μg/ml propidium iodide and 1mg/ml RNase A (Sigma). Cells 
were analyzed on a FACSCalibur (Becton Dickinson). 
 
2.1.25 alamarBlueTM proliferation assay 
Cells per well were plated overnight in 24-well plates, following which 10% 
alamarBlueTM solution (BioSource International Inc.) in DMEM was added to each 
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well. Fluorescent measurements were taken by reading each plate in a Tecan 
SPECTRAFluor plate reader (Tecan Trading AG, Switzerland) with excitation at 
535nm and emission at 590nm. Plates were read immediately after adding 
alamarBlueTM solution (T0) and incubated for 2 hours before taking a second reading 
(T2h). The T2h readings were normalized against T0 readings to determine the change 
in fluorescence units, which were indicative of cell proliferation rate. 
 
2.1.26 Senescence-associated beta galactosidase (SA-β-Gal) assay 
Cells were stained for SA-β-Gal activity as an indication of senescence induction. 
This assay was performed using the SA-β-Gal staining kit (Cell Signaling 
Technology). Briefly, cells were plated in 6-well plates or on coverslips and fixed in 
2% formaldehyde/0.2% glutaraldehyde/1x PBS solution for 20 minutes at room 
temperature. After washing thrice in 1x PBS, cells were incubated overnight at 37 oC 
in staining solution containing 5mM potassium ferrocyanide, 5mM potassium 
ferricyanide, 40mM citric acid/sodium phosphate (pH 6), 0.15 NaCl, 2mM MgCl2 and 
1mg/ml X-gal. The cells were then washed twice in 1x PBS and visualized using light 
microscopy. Cells were kept in 70% glycerol at 4oC for long term storage. 
 
2.1.27 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 3.0 or 4.0 software. The 
Mann-Whitney test was used to analyze statistical differences between unpaired 
samples, and one-way ANOVA with Bonferroni’s post test was used to compared 
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2.2 Primers for PCR 
 
p16: Forward 5’-AGGCTCTGAGAAACCTCGGGAAA-3’  
and Reverse 5’-AATGGACATTTACGGTAGTGGGGGAAG-3’ 
 
NDRG1: Forward 5’-GGGCGGAATTGGGGTTACTC-3’ 
and Reverse 5’-CCACCCCGACAAGAGCAAAG-3’ 
 
Full length NDRG1: Forward 5’-GCAGGTGACAGCAGGGACAT-3’ 
and Reverse 5’-GCAGGAGACCTCCATGGACTT-3’ 
 
NDRG1-Flag (reverse primer): 5’-GTC GTC ATC CTT GTA ATC GCA GGA GAC 
CTC CAT GGA CT-3’ 
 
C-Flag (reverse primer): 5’-CTACTTATCGTCGTCATCCTT-3’ 
(Flag peptide sequence: KDDDDKYD) 
 
RB: Forward 5’-CAGATGCAATTGTTTGGGTG-3’  
and Reverse 5’-TGAATGGGCAGTCAATCAAA-3’ 
 
p53: Forward 5’-TGGAAGGAAATTTGCGTGTG-3’  
and Reverse 5’-AAGGCCTCATTCAGCTCTCG-3’ 
 
p21: Forward 5’-CAGGCGCCATGTCAGAAC-3’  
and Reverse 5’-GGATTAGGGCTTCCTCTTGG-3’ 
 
E6: Forward 5’-AATGTTTCAGGACCCACAGG-3’  
and Reverse 5’-TCAGGACACAGTGGCTTTTG-3’ 
 
E7: Forward 5’-TGTTAGATTTGCAACCAGAGA CA-3’  
and Reverse 5’-GAACAGATGGGGCACACAAT-3’ 
 
M13: Forward 5´-GTAAAACGACGGCCAG-3´ 
And Reverse 5´-CAGGAAACAGCTATGAC-3´ 
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18S rRNA: Forward 5’-CCTGCGGCTTAATTTGACTC-3’  
and Reverse 5’-CGCTGAGCCAGTCAGTGTAG-3’ 
 
β-actin: Forward 5’- GTGATGGTGGGCATGGGTCA-3’ 
and Reverse 5’- TTAATGTCACGCACGATTTCCC-3’ 
 
 
2.3 siRNA sequences 
p16 (Oligoengine, USA): Forward 5’-CGCACCGAAUAGUUACGGUTT-3’  
and Reverse 5’-ACCGUAACUAUUCGGUGCGTT-3’ 
p16 siRNA is used at a final concentration of 20nM in each transfection. 
 
NDRG1 (Stealth RNAi, Invitrogen): 
Sequence 1 – Forward 5’-UUUAGAGCAAAUCGAGUUAGGAUGU-3’  
and Reverse 5’-ACAUCCUAACUCGAUUUGCUCUAAA-3’ 
Sequence 2 – Forward 5’-AUAAGGACAAGGCCCUCCACCAUCU-3’  
and Reverse 5’-AGAUGGUGGAGGGCCUUGUCCUUAU-3’ 
Both sequences (50nM each) are combined to a final concentration of 100nM in each 
transfection. 
 
p53 (Stealth RNAi, Invitrogen): 
Sequence 1 – Forward 5’-UUUAGCUCUCGGAACAUCUCGAAGC-3’ 
and Reverse – Forward 5’-GCUUCGAGAUGUUCCGAGAGCUGAA-3’ 
Sequence 2 – Forward 5’-UGAACCAUUGUUCAAUAUCGUCCGG-3’ 
and Reverse 5’-CCGGACGAUAUUGAACAAUGGUUCA-3’ 
Both sequences (25nM each) are combined to a final concentration of 50nM in each 
transfection. 
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2.4 Buffers 
2.4.1 General buffers 
TfbI buffer (preparation of competent cells) – 30mM KOAc; 100mM Rubidium 
Chloride (RbCl); 10mM CaCl2⋅2H2O; 50 mM MnCl2⋅4H2O; 15% (v/v) glycerol; adjust 
pH to 5.8 with 2M acetic acid 
 
TfbII buffer (preparation of competent cells) – 10mM MOPS; 75 mM CaCl2⋅2H2O; 
10mM RbCl; 15% (v/v) glycerol; adjust pH to 6.5 with diluted NaOH 
 
LB broth – 1% (w/v) Bacto-tryptone; 0.5% (w/v) Bacto-yeast extract; 1% (w/v) NaCl. 
For LB agar, add 15g/L agar before autoclaving. 
 
 
SOC media – 2% bactotryptone; 0.5% yeast extract; 10mM NaCl; 2.5mM KCl; 10mM 
MgCl2; 10mM MgSO4; 20mM glucose 
 
TE Buffer – 10mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0 
 
TBE buffer – 89mM Tris-base; 89mM boric acid; 2mM EDTA 
 
Phosphate buffered saline – 137mM NaCl; 2.7mM KCl; 4.3mM Na2HPO4; 1.4mM 
KH2PO4; pH 7.4 
 
20x SSC – 3M NaCl, 0.3M tri-sodium citrate, adjust pH to 7.0 
 
2.4.2 Buffers for protein analysis 
Lysis Buffer – 10mM Tris-HCl (pH 7.4); 150mM NaCl; 1mM EDTA; 1% Triton X-100; 
0.5% NP-40; 1x Complete protease inhibitor cocktail (Roche, Germany) 
 
2x sample loading buffer – 0.125M Tris, pH 6.8; 4% (w/v) SDS; 20% (v/v) glycerol; 
2% (v/v) β-mercaptoethanol; 0.005% (w/v) bromophenol blue. 
 
10x electrophoresis buffer – 25mM Tris, pH 7; 250mM glycine; 0.1% SDS 
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1x transfer buffer – 39mM glycine; 48mM Tris-Base; 0.037% (w/v) SDS; 20% 
methanol 
 
1x Tris/CAPS buffer (Bio-Rad) – 10mM 3-[cyclohexylamino]-1-propane sulfonic acid, 
pH 11 with NaOH, 10% methanol 
 
Stripping buffer – 100mM β-mercaptoethanol; 62.5mM Tris-HCl, pH 7; 2% SDS / 
Restore stripping buffer (Pierce Biotechnology). 
 
Blocking buffer – 5% skim milk; 0.05% Tween 20 in PBS. 
 
SDS-PAGE Gels – 30% Acrylamide/Bis solution 37.5:1 (Bio-Rad) 
 
Table 2-2. Recipe for SDS-PAGE gels 
























0.5M Tris, pH 6.8 
(stacking gels) 


























TOTAL 15.01 ml 15.01 ml 15.01 ml 10.0 ml 
 
 
2.4.3 Reagents and buffers for Affymetrix GeneChip system 
GeneChip T7-Oligo(dT) Promoter Primer:  
5´-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24 -3’ , 50μM, 
HPLC purified 
 
GeneChip® IVT Labelling Kit Components (30 reactions): 10x IVT labelling buffer, 
IVT labelling enzyme mix, IVT labelling NTP mix, 3’-labelling control (0.5μg/uL), 
RNase-free water 
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GeneChip® Hybridization control kit components (30 reactions): Each kit contains 
20x hybridization control solutions composed of pre-mixed biotin-labelled bioB, bioC, 
bioD and cre and control oligo B2. These controls are necessary for monitoring the 
hybridization process to facilitate troubleshooting. 
5x fragmentation buffer – 200mM Tris-acetate, pH 8.1; 500mM KOAc; 150mM 
MgOAc 
 
12x MES Stock buffer (1.22M MES; 0.89M [Na+]) 
  70.4 g  MES free acid monohydrate (Sigma) 
193.3 g  MES sodium salt (Sigma) 
 800 ml  ddH2O 
 
Mix and adjust volume to 1000 ml. The pH should be adjusted between 6.5 and 6.7. 
Filter through 0.2 μm filter. Store at 4 oC, and shield from light. 
 
 
2x Hybridization buffer (200mM MES; 2M [Na+]; 40mM EDTA, 0.02% Tween 20) 
  8.3 ml 12x MES stock buffer 
   17.7 ml  5 M NaCl 
     4 ml 0.5 M EDTA 
  0.1 ml 10% Tween 20 
   19.9 ml ddH2O 
Filter through 0.2 μm filter. Store at 4 oC, and shield from light.  
 
2x Stain buffer (200mM MES; 2M [Na+]; 0.1% Tween 20) 
41.7 ml 12x MES stock buffer 
92.5 ml  5 M NaCl 
  2.5 ml 10% Tween 20 
  113.3 ml dH2O 
Filter through 0.2 μm filter. Store at 4 oC, shield from light.  
 
Streptavidin phycoerythrin (SAPE) solution (1x MES; 2mg/ml acetylated BSA; 
10μg/ml SAPE) 
600 μl 2x Stain buffer 
  48 μl 50 mg/ml acetylated BSA 
  12 μl 1 mg/ml Phycoerythrin streptavidin (Molecular Probes) 
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Biotinylated anti-streptavidin IgG solution (1x MES; 2mg/ml acetylated BSA; 
100μg/ml normal goat IgG; 3μg/ml biotinylated anti-streptavidin IgG) 
 
300 μl 2x Stain buffer 
  24 μl 50 mg/ml acetylated BSA 
    6 μl 10 mg/ml normal goat IgG (Sigma) 
 3.6 μl  0.5 mg/ml biotinylated anti-streptavidin IgG (Vector Laboratories) 
 266.4 μl ddH2O 
 
20x SSPE – 3M NaCl; 0.2M NaH2PO4; 0.02M EDTA; adjust pH to 7.4 
 
Wash A (Non-stringent wash buffer) (6x SSPE, 0.01% Tween 20) 
   300 ml  20x SSPE 
    1.0 ml 10% Tween-20 
   699 ml  ddH2O 
 
Filter through 0.2 μm filter 
 
Wash B (Stringent wash buffer) (100mM MES; 0.1 M [Na+]; 0.01% Tween 20) 
83.3 ml 12x MES stock buffer 
 5.2 ml 5 M NaCl 
    1 ml 10% Tween 20 
 910.5 ml ddH2O 
 
Filter through 0.2 μm filter, store at 4 oC and shield from light. 
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CHAPTER 3 
Identification of differentially expressed genes in cervical cancer by microarray analysis 
of subtracted cDNA libraries 
 
3.1 Summary          63 
3.2 Results 
 3.2.1 Subtracted cDNA library construction and screening   64 
 3.2.2 Expression profiling of cervical tissues studied in spotted cDNA  
    microarrays         65 
 3.2.3 Identification of differentially expressed genes in cervical cancer  69 
3.3 Discussion         70 
3.4 Conclusion         74 
 
3.1 Summary 
Tumorigenesis is a multi-step process involving a vast molecular network of genes 
whose expression patterns might be specifically modified with progression of the 
disease. We employed subtracted cDNA libraries in conjunction with spotted microarray 
analysis to compare gene expression profiles between tumour and normal tissues, with 
the aim of identifying differentially expressed genes in cervical cancer. To enrich for low 
copy number genes that are differentially expressed in cervical cancer, we used the 
Clontech PCR-Select cDNA subtraction kit to construct 2 reciprocal subtracted cDNA 
libraries using total RNA from tumor and non-tumourous cervical tissue from a single 
cervical cancer patient with Stage 1B disease. A total of 1920 cDNA clones obtained 
from both libraries were used to generate spotted cDNA microarrays. After screening 30 
tumor samples and 20 non-tumourous tissues from cervical cancer patients, as well as 
12 normal cervical tissues using microarray analysis, we identified several gene 
clusters that were differentially expressed in cervical cancer. These genes were 
matched with sequence information available in GenBank databases, and were 
classified as known, unknown or EST genes from each cluster. Our data suggest that 
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alteration in gene expression profiles resulting from presumably normal tumour-
adjacent cervical tissue may be indicative of early neoplastic or progressive changes 
that eventually lead to invasive cancer of the cervix. The identification of such genes 




3.2.1 Subtracted cDNA library construction and screening 
The two reciprocal subtracted cDNA libraries (forward and reverse) were constructed 
using RNA extracted from a tumourous and non-tumourous cervical tissue taken from a 
Stage 1B cervical cancer patient. A total of 1920 clones were obtained from the forward 
and reverse subtracted libraries, 1108 clones from the forward library (where tumour 
tissue is used as the ‘tester’ and the non-tumourous tissue is the ‘driver’) and 812 
clones from the reverse library (non-tumourous tissue used as ‘tester’, tumourous tissue 
as the ‘driver’). To assess the complexity of the library, we randomly selected 200 
clones for sequencing and of these 90% were unique sequences, demonstrating that 
the majority of the clones were not overlapping. These clones were PCR amplified and 
used to generate cervical cancer-related spotted cDNA microarrays. In addition to these 
clones, we also included the housekeeping genes, β-actin, α-tubulin, GAPDH, beta-2-
microglobulin, ubiquitin, and cyclophilin, and negative-control plant genes, amino-
cyclopropane carboxylate oxidase (ACCO) and flavanone 3-hydroxylase (F3H). These 
1928 elements were spotted in duplicate resulting in a total of 3856 spot elements on 
each microarray. Using these microarrays, we screened the subtracted cDNA libraries 
using 30 tumour samples and 20 non-tumourous tissues from cervical cancer patients, 
and 12 normal cervical tissues. A representative pseudo-colour microarray image is 








Figure 3-1. Representative microarray image. Each microarray contains a total of 
3856 spot elements and is hybridized with reference cDNA (Cy3-fluorescent labelled) 
and Cy5-fluorescent labelled tester samples such as tumour, non-tumourous or normal 
cDNA. Yellow, red and green spots represent unchanged, increased and decreased 
gene expression respectively. 
    
 
 
3.2.2 Expression profiling of cervical tissues studied in spotted cDNA 
microarrays. 
After hybridization of microarrays to patient samples and scanning of microarrays, we 
carried out post-hybridization filtering by excluding the signals that were 
indistinguishable from background noise, as well as non-concordant duplicates or 
incomplete spots due to technical inconsistencies.  We obtained a total of 1102 spot 
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elements after filtering, and their signal intensities across all patient samples were 
visualized as 2-dimensional hierarchical graphs using Cluster and Treeview software 
available from the Eisen Lab at Lawrence Berkeley National Lab 
(http://rana.lbl.gov/EisenSoftware.htm). Figure 3-2 shows the entire Treeview diagram 
generated from microarray screening of patient samples, with representative clusters of 
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Non-tumourousNormal












Figure 3-2. Hierarchical clustering of microarray gene expression data. The color 
bar on the top shows the arrangement of tissue samples; black: normal cervical tissue, 
red: non-tumourous tissue and blue: tumour tissue respectively. The samples fall into 
three distinct groups. The left-most panel shows the gene expression of 1102 genes (y-
axis) in the 43 biopsies samples we used. Red, green and black squares within the 
cluster-gram represent up-regulated expression, down-regulated expression and 
unchanged expression respectively. Various gene clusters are highlighted in larger 
magnification on the right (Clusters A-D). 
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From the clustergram, we were able to distinguish tumour samples from non-tumourous 
and normal cervical tissue samples based on different colour patterns, indicating that 
the gene expression profiles differed between tumour, non-tumourous and normal 
cervical tissue. However, we did not observe significant differences of gene expression 
between various tumour stages. Based on the Treeview hierarchical clustergram, we 
sequenced various clusters of clones which showed differential gene expression 
profiles between tumour and non-tumourous samples.  
 
Cluster A consisted of genes such as CDKN2A, which were up-regulated in tumour 
samples compared to normal cervical tissue samples  Cluster B represented genes 
down-regulated in tumour as compared to non-tumourous and normal cervical tissue 
samples, including keratin 4, S100 calcium binding protein A8 (S100A8), serine 
protease inhibitor (SPINK5L3), T-cell differentiation protein and small proline rich 
protein 1 gene (SPRR1A). Cluster C consisted of genes down-regulated in tumourous 
compared to normal cervical tissue, with no apparent difference between tumourous 
and non-tumourous cervical tissues. However, gene expression levels between non-
tumourous and normal cervical tissues appeared to be different, hence these gene 
expression alterations in non-tumourous cervical tissue (which are tumour-adjacent) 
may be indicative of early neoplastic or progressive changes. Genes in Cluster C 
included vimentin, keratin 13, connexin 30, ring-box protein 1 and clusterin genes. 
Cluster D comprised of genes up-regulated in tumour samples compared to non-
tumourous and normal cervical tissue samples. Several independent clones of N-myc 
downstream regulated gene 1 (NDRG1) as determined by non-identical clone sequence 
were found in this cluster, suggesting that this gene may be amplified in cervical cancer 
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3.2.3 Identification of differentially expressed genes in cervical cancer 
At the same time, we also performed Student’s t-test statistical analyses to identify 
genes which were most significantly differentially expressed in cervical tumour tissue 
compared to non-tumourous and normal tissue. Table 3-1 shows the expression of 26 
genes which were most significantly altered between tumour, non-tumourous and 
normal cervical tissue samples. Of the 17 up-regulated genes, we found CDKN2A (p16), 
NDRG1 and RANBP1 to have the highest differential expression in tumour compared to 
non-tumourous and normal samples. We observed down-regulation of 9 genes, 
including EGR1, RBX1 and CLU which showed the most drastic down-regulation fold 
change in tumour compared to non-tumourous and normal cervical tissues. Many of the 
26 genes were also significantly differentially expressed between non-tumourous and 
normal cervical tissue, suggesting that these genes might be involved in early 






























Section 3 – Results and Discussion 
 
Table 3-1. Twenty-six differentially expressed genes in cervical cancer compared 
to non-tumourous and normal controls 
p -value* Fold Change
Gene Name Accession No. N vs NT N vs T NT vs T Mean (T/N)
Up-regulated genes (17)
Ribosomal protein, large, P0 (RPLP0) NM_001002 NS 1.21E-11 2.95E-06 2.1
N-myc dow nstream regulated gene (NDRG1) NM_006096 NS 2.16E-08 4.90E-06 3.3
Keratinocyte grow th factor receptor 2 (FGFR2) NM_000141 NS 1.11E-08 2.59E-06 2.0
GTP-binding protein RAB21 NM_014999 NS 1.27E-08 9.85E-06 1.8
Cyclin-dependent kinase inhibitor 2A (CDKN2A, p16) NM_000077 NS 9.94E-10 1.63E-05 3.8
ATP synthase, subunit F2 (ATP5J2) NM_004889 NS 1.92E-07 2.28E-04 1.8
Osteopontin (SPP1) NM_000582 5.36E-05 1.37E-08 1.82E-06 2.2
Egl nine homologue 1 (C. elegans) NM_022051 NS 7.58E-07 4.85E-06 2.3
H2A histone family, member Z (H2AFZ) NM_002106 8.20E-04 6.11E-06 3.77E-05 1.9
Cytochrome P450, subfamily IIIA (CYP3A) 4.78E-04 6.58E-05 2.00E-03 1.3
Triosephosphate isomerase 1 (TPI1) NM_000365 1.64E-03 2.30E-05 3.86E-04 1.7
HPV type 16 variant complete seq (HPV16) 2.91E-03 6.54E-04 1.81E-03 1.5
Similar to karyopherin alpha 1 (importin alpha 5) (KPNA1) NM_002264 NS 4.36E-04 1.96E-04 1.6
RAN binding protein 1 (RANBP1) NM_002882 8.58E-03 1.60E-03 1.67E-03 1.5
Keratin 6A (KRT6A) NM_005554 NS 4.61E-04 1.36E-02 3.3
Keratin 13 (KRT13) NM_002274 9.54E-06 1.19E-05 NS 2.0
Keratin 16 (KRT16) NM_005557 2.73E-02 3.01E-04 NS 1.9
Down-regulated genes (9)
Early grow th response 1 (EGR1) NM_001964 6.26E-08 2.84E-03 1.10E-04 5.0
Keratin 4 NM_002272 NS 1.01E-07 2.76E-03 6.0
T-cell differentiation protein (MAL) NM_002371 NS 1.69E-04 9.89E-04 4.0
Serine protease inhibitor (SPINK5L3) NM_001040129 NS 9.03E-05 1.48E-03 4.2
S100 calcium binding protein A8 (S100A8) NM_002964 NS 8.05E-05 2.22E-05 1.5
Small proline-rich protein 1 gene (SPRR1A) NM_005987 4.41E-06 4.93E-05 3.65E-04 2.3
Ring-box 1 (RBX1) NM_014248 5.32E-05 2.20E-02 NS 1.7
Clusterin (CLU) NM_001831 7.62E-05 1.90E-03 NS 2.5
Purkinje cell protein 4 (PCP) U52969 2.13E-05 1.65E-03 1.75E-02 2.1
* T: tumourous cervical tissue, NT: non-tumourous cervical tissue, N: normal cervical tissue 




Invasive carcinoma of the cervix develops from well-defined precursor lesions known as 
cervical intraepithelial neoplasias (CINs) at the squamocolumnar junction. During 
carcinogenesis, it is likely that the tumor-adjacent tissues undergo molecular 
transformation as a result of altered gene expression. Identification of such genes will 
contribute toward elucidating the early molecular events and mechanisms associated 
with cervical carcinogenesis and our objective is to isolate differentially expressed 
genes which have not been previously identified in cervical cancer, and which may be 
of use as diagnostic or prognostic markers. Using a combination of cDNA subtraction 
and microarray techniques, we were able to identify 26 significantly differentially 
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expressed genes in cervical tumours compared to non-tumourous and normal cervical 
tissues.  
 
We observed that a number of genes including SPP1, RANBP1, EGR1, RBX1, CLU 
and PCP4 (see Table 3-1) were significantly differentially expressed between non-
tumourous cervical tissue and normal cervical tissue. This may indicate gene 
expression changes in the non-tumourous cervical tissue adjacent to the tumour, and 
hence these genes may be involved in early neoplastic changes in cervical 
carcinogenesis. However, it is difficult to rule out biological differences in tissue biopsies 
which may occur during sampling, or to exclude inherent differences in squamous 
epithelia in the transformation zone, hence further analysis of a larger cohort of samples 
using immunohistochemical methods is required. 
 
Among the up-regulated genes, we observed that the HPV type 16 gene was up-
regulated in all cervical tumour samples compared to non-tumourous and normal 
samples, hence confirming that all the cervical tumours contained HPV high-risk type 
16 DNA. Three of the highest up-regulated genes included CDKN2A (p16), N-myc 
downstream regulated gene 1 (NDRG1) and Ran binding protein 1 (RANBP1) genes. 
Our results show that p16 was consistently up-regulated in all cervical tumors 
compared to non-tumourous and normal cervical tissue. p16 is a cyclin dependent 
kinase inhibitor that plays an important role in cell cycle regulation via the Rb pathway, 
and has been found to be inactivated in many cancers through mutation, deletion or 
hyper-methylation of the gene (107). Others have also reported p16 over-expression 
using immunohistochemical studies of cervical cancer and gene expression profiling 
(156, 157), but its functional role in cervical cancer is unknown. To our knowledge, the 
up-regulation of NDRG1 and RANBP1 has not been previously reported in cervical 
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cancer. NDRG1 has been implicated as a putative metastasis suppressor in breast, 
prostate and colon cancers (153), and RANBP1 is a Ras-like nuclear G protein that 
participates in G-protein signalling and GTP hydrolysis (158).  
 
In addition to up-regulated genes, we also observed significant down-regulation of 
genes including clusterin (CLU), ring-box protein 1 (RBX1) and early growth response 1 
(EGR1). CLU encodes for a 53 kDa protein which is expressed in most human tissues 
such as brain, ovary, testis, liver, heart, spleen, lung, and breast (159). The clusterin 
protein is involved in numerous physiological processes including apoptosis, cell cycle 
regulation, DNA repair, cell adhesion, immune regulation and morphological 
transformation. Increased CLU mRNA and protein levels have been consistently 
detected in heart, brain, liver, kidney, breast, and retinal tissues undergoing stress, both 
in vivo and in vitro. Importantly, CLU up-regulation has been reported in various human 
malignancies, including bladder, kidney, prostate, colon, breast and lung tumours (160). 
Recently, one study has linked found high CLU expression in cervical tumours 
compared to normal tissue, and has linked CLU expression to paclitaxel resistance 
(161).  
 
RBX1, a RING finger protein, is a component of the SCF (Skp-Cul1-F-box protein) 
complex and the VHL ubiquitin ligase complexes, both of which mediate ubiquitination 
and subsequent proteasome degradation of proteins involved in cell transcription, signal 
transduction and cycle progression (162, 163). Since protein degradation is crucial and 
highly selective during cell cycle progression, it is possible that down-regulation of Rbx1 
may lead to aberrations in cell cycle progression, thereby contributing to tumorigenesis. 
The EGR1 gene encodes a zinc finger protein of 59 kDa. Egr1 is a transcription factor 
that has tumour suppressor properties which are largely mediated through p53 and also 
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TGFβ1 (164). Recent studies have also revealed that Egr1 is able to regulate the 
tumour suppressor PTEN, the anti-apoptotic gene BCL2, p73 (a p53-homologue) as 
well as fibronectin (165). Hence, EGR1 participates in the regulation of a vast network 
of suppressor genes. In contrast, EGR1 is over-expressed in prostate cancer and has 
been reported to play a role in tumour progression by down-regulating genes involved 
in cell cycle and apoptosis  (166, 167). In either case, EGR1 may be an important target 
in anti-cancer therapy, and we report for the first time that EGR1 is down-regulated in 
cervical cancer. 
 
Other studies employing microarray analysis in cervical cancer have also identified the 
differential regulation of p16, SPP1, SPINK5L3, SPRR1A, MAL and S100A8 (157, 168), 
but the rest of the genes in our cervical cancer-related cDNA subtracted library have not 
been previously reported in relation to cervical cancer, thus showing the effectiveness 
of this library in identifying novel differentially regulated genes in cervical cancer. 
Although p16 has been previously reported to be up-regulated in cervical cancer, its 
high expression is at odds with its known role as a cell cycle inhibitor and tumour 
suppressor, hence we were interested to elucidate its functional role in cervical cancer. 
Similarly, we were also interested in the role of NDRG1 in cervical carcinogenesis, as it 
has not previously been implicated in cervical cancer. 
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3.4 Conclusion 
Using a combination of cDNA subtractive library cloning and microarray analysis, we 
have identified a number of differentially regulated genes in cervical tumours compared 
to non-tumourous and normal cervical tissues. These findings may provide new 
avenues for investigating the molecular pathogenesis of cervical cancer, and the 
mechanism behind the differences in the expression of these genes remains to be 
further investigated. We have focused particularly on the study of p16 and NDRG1 
genes, as they were shown to be significantly up-regulated in cervical cancer. The 
function of these two genes in cervical cancer is not well known, and we describe in 
detail the characterization of their functional role in cervical cancer in the following 
Chapters 4 and 5. 
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CHAPTER 4 
p16INK4A silencing augments DNA damage-induced apoptosis in cervical cancer 
cells 
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p16INK4A (p16) has been suggested to be an early biomarker for the detection of cervical 
cancer.  However, its functional role in cervical cancer is not well characterized.  In this 
study, we reported the consistent and significant up-regulation of p16 in cervical cancer 
tissues when compared to both non-tumourous tissues of the same patient and normal 
cervical tissues from non-cancerous patients.  We have employed p16 siRNA to dissect 
the role of p16 in cervical carcinogenesis.  Although the silencing of p16 was 
accompanied by the up-regulation of p53, p21 and RB in the p16 siRNA-transfected 
cells, no significant effect on cell cycle progression was observed.  When the p16 
siRNA-silenced cells were subjected to DNA damage stresses including UV irradiation 
and cisplatin treatments, a significantly higher percentage of apoptotic cells could be 
observed in the p16-siRNA silenced cells compared to control siRNA-treated cells.  
Moreover, induction of apoptosis was associated with the activation of p53 through 
phosphorylation, and this process, when studied by gene profiling experiments, 
involved both the intrinsic and extrinsic apoptotic pathways.  The observation that 
silencing of p16 expression augments DNA damage-induced apoptosis in cervical 
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4.2 Results 
4.2.1 Significant up-regulation of p16 gene expression in squamous cell cervical 
carcinoma.  
Amongst the genes over-expressed in cervical cancer, as screened by our spotted 
cDNA microarrays, p16 was shown to be significantly up-regulated in 30 cervical 
tumour tissues compared to 20 non-tumourous tissues (p<0.01) and to 12 normal 
cervical tissues (p<0.001; Figure 4-1A). Reverse transcription-quantitative real time 
PCR using a further 6 samples each of tumour, non-tumourous and normal cervical 
tissue confirmed up to 200-fold p16 up-regulation in cervical carcinoma compared to 















































Figure 4-1. Significant up-regulation of p16 gene expression in cervical cancer. 
Gene expression of p16 in normal (N), non-tumourous (NT) or tumour (T) samples as 
determined by (A) cDNA library screening using spotted cDNA microarrays and (B) real 
time PCR analysis. Sample size is indicated by ‘n’. Bars represent median values and (*) 
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4.2.2 High expression of the p16 gene is predominantly found in uterine cancer 
tissue among 8 human cancers studied.  
p16 is a tumor suppressor gene which is frequently reported to be inactivated or 
mutated in most human cancers. Herein we demonstrated the up-regulation of p16 in 
cervical cancer, hence we decided to assess the level of p16 gene expression in other 
human cancers using Clontech multiple tissue northern (MTN) blot. Our result revealed 
that p16 was highly expressed in uterine cancer, compared to the other human cancers 
studied (Figure 4-2). p16 gene expression could also be detected in lung cancer but not 
in any of the other human cancers including rectum, colon, stomach, kidney, ovary and 
breast cancers. This confirms that p16 up-regulation in cervical cancer is found 



























Figure 4-2. p16 gene expression in 8 human cancers. Expression level of p16 high 
in predominantly uterine cervical cancer but is low in lung cancer and is not detectable 
in rectum, colon, stomach, kidney, ovarian and breast cancer. The Northern blot 
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4.2.3 Detection of endogenous p16 mRNA and protein expression in Cas Ki and 
SiHa cervical cancer cell lines. 
In contrast to many human cancers where p16 is inactivated, over-expression of p16 in 
cervical cancer may have significant impact on the development of cervical cancer. We 
employed SiHa and Cas Ki cells for our present study specifically because they are 
derived from squamous cell carcinoma of the cervix, and contain the HPV type 16 viral 
genome, similar to the tumour samples obtained from cervical cancer patients and 
employed in our microarray studies. As shown by Figure 4-3, both cell lines express 




Ca Ski   SiHa
β-actin
p16




Figure 4-3. Endogenous p16 mRNA and protein expression level in Cas Ki and 
SiHa cervical cancer cell lines. (A) Western blot and (B) Northern blot analysis shows 
high expression of endogenous p16 protein and mRNA respectively in Cas Ki and SiHa 
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4.2.4 siRNA-mediating silencing of p16 in SiHa cervical cancer cells. 
To gain insight into the role of p16 in cervical cancer, SiHa cervical cancer cells were 
monitored after transfection with short interfering RNAs (siRNAs) that target exon 1α of 
the p16 gene. We transfected SiHa cells with p16 siRNA at concentrations of 15nM and 
20nM for 24, 48 and 72 hours to determine the effectiveness of p16 siRNA. We 
observed that p16 protein levels reduced dramatically 24 hours after siRNA transfection, 










































Figure 4-4. siRNA-mediated silencing of p16 in SiHa cells. Western blot analysis of 
total cell lysate showed the silencing of p16 protein expression 24, 48 and 72 hours 
after transfection of p16 siRNA at various concentrations. Nil represents control siRNA 
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4.2.5 p16 siRNA specifically inhibits expression of p16 but not p14ARF, encoded 
by the same gene locus as p16. 
We achieved 95% reduction in p16 protein expression after a 24-hour transfection of 
cells with p16 siRNA (Figure 4-5A and 4-5B), and 55% reduction in p16 mRNA was 
achieved (Figure 4-5C) in both SiHa and Cas Ki cells. The control siRNA sequence had 
no effect on p16 mRNA or protein, thus confirming that the reduction in p16 was 
sequence-specific and not due to random effects of siRNA transfection. More 
importantly, p14 protein expression encoded by the same gene locus but a different 
reading frame to p16, was not affected (Figure 4-5A and 4-5B), confirming that the p16 
siRNA targeting effect was highly specific for p16. 
 


































































































Figure 4-5. p16 siRNA specifically inhibits expression of p16 but not p14ARF, 
encoded by the same gene locus as p16. (A) The expression of p16 and p14 were 
determined by Western blot in SiHa cells at 24h after transfection with p16 siRNA (+) or 
control siRNA (-). The results shown are representative of 2 independent experiments. (B) 
Densitometric analysis of protein bands was performed. After normalization to β-actin, 
relative protein expression levels were determined in relation to control siRNA, which were 
given an arbitrary value of 100. (C) Real-time PCR quantitation of p16 mRNA levels in SiHa 
cells after p16 siRNA silencing. The relative mRNA levels were determined in relation to 
control siRNA, which was given an arbitrary value of 100. 
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4.2.6 Silencing of p16 modulates expression of Rb, E7, p53 and p21 in cervical 
cancer cell lines 
As p16 is a key member of the RB tumour suppressor pathway, we monitored 
expression of Rb in SiHa and Cas Ki cells at 12, 24 and 48 hours after p16 siRNA 
transfection. Although no significant change of Rb mRNA level was detected (Figure 4-
6A), Rb protein expression was increased in the p16-silenced cells compared to control 
siRNA-treated cells (Figure 4-6B), suggesting that p16 affects Rb protein expression 
post-transcriptionally. We observed that p16-silencing down-regulated the expression of 
E7 (Figure 4-6A). It is known that E7 can degrade Rb protein directly in HPV-positive 
cervical cancer cells, therefore this may explain the increase of Rb protein in p16-
silenced cells. On the other hand, E6, another HPV viral oncoprotein which binds and 
degrades p53, did not show altered expression in p16-silenced cells (Figure 4-6A). 
Although E6 remained unchanged, we observed increased levels of p53 gene and 
protein expression (Figure 4-6A and 4-6B), suggesting that p16 silencing enhanced p53 
expression independently of E6. Furthermore, this was accompanied by a sharp 
increase in protein expression of p21, a p53-downstream transcriptional target (Figure 
4-6B). Taken together, this shows that p16 silencing results in alteration in proteins 
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Figure 4-6. Silencing of p16 modulates expression of Rb, p53, E6 and E7 in 
cervical cancer cell lines. SiHa and Cas Ki cells were treated with p16 or control 
siRNA and assayed at 12h, 24h and 48h. (A) mRNA expression levels were determined 
by real-time PCR analysis in SiHa cells. The relative mRNA levels were determined in 
relation to control siRNA, which was given an arbitrary value of 100. (*) indicates 
significant p-value <0.01. (B) Western blot analysis was performed using total cell lysate 
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4.2.7 Silencing of p16 has no effect on cell cycle progression in SiHa cervical 
cancer cells.  
Induction of p53 and concomitant activation of p21 has been associated with G1 growth 
arrest. We performed cell cycle analysis and found that despite high levels of p53 and 
p21 in p16-silenced cells, G1 and S-phase cell populations remained consistent at 
approximately 60% and 30% respectively from 24 to 72 hours after p16 siRNA 
transfection (Figure 4-7A). We conducted BrdU proliferation studies which showed that 
the cells did not stop proliferating (Figure 4-7B). Furthermore, no significant number of 
dead cells was observed up to 72 hours post-transfection, as judged by floating cells 
during culture. Propidium iodide DNA-staining profiles did not show sub-G1 apoptotic 
peaks, which confirmed that these cells were not undergoing apoptosis. Hence, up-
regulation of p53 and p21 in p16-silenced cells did not result in cell cycle arrest, 
apoptosis, or a decrease in cell growth.  

































Figure 4-7. Silencing of p16 has no effect on cell cycle progression in SiHa cells. 
The cell proliferation status of SiHa cells after 24h, 48h and 72h transfection of p16 
siRNA or control siRNA analysis were determined by (A) Cell cycle analysis by 
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4.2.8 Silencing of p16 augments UV- and cisplatin-induced apoptosis in SiHa 
cervical cancer cells.  
To determine the role of p16 in response to DNA damage, cervical cancer cells 
transfected with p16 siRNA or control siRNA were subjected to 100J/m2 UV irradiation 
or 20μM cisplatin treatment. A significantly higher percentage of apoptotic cells was 
observed in p16-silenced SiHa cells compared to control siRNA-treated cells (Figure 4-
8), indicating that p16 may play an anti-apoptotic role. At 12 hours after UV treatment, 
the proportion of apoptotic cells in the p16 siRNA-transfected cells was 5% compared to 
1.5% in the control-treated cells (p<0.05). At 24 hours post-UV irradiation, the 
percentage of apoptotic cells increased to 19% for p16-silenced cells compared to 4% 
in the control (p<0.001), and at 48 hours, induction of apoptosis was 28% for p16-
silenced cells compared to 6.5% for the control (p<0.001).  
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Figure 4-8. Silencing of p16 augments UV- and cisplatin-induced apoptosis in 
SiHa cervical cancer cells. After transfection with p16 siRNA or control siRNA, SiHa 
cells were then subjected to 100J/m2 UV-irradiation or cisplatin (20μM). Cells were fixed 
and stained with propidium iodide (100μg/ml) for FACS analysis at 12h, 24h and 48h. 
Percentage of apoptotic cells were determined by sub-G1 populations. (*) indicates 
significant p-value <0.01. (***) indicates significant p-value <0.001. Data were collected 
from 3 independent experiments. 
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Similarly, after 20μM cisplatin treatment, apoptotic cell populations were significantly 
higher in p16 siRNA-transfected SiHa cells compared to controls (Figure 4-8). After 12 
hours of exposure to cisplatin, p16-silenced cells showed 32% apoptotic cell population 
compared to 13% in control cells; at 24 hours after cisplatin treatment, the apoptotic 
population for p16-silenced cells was 41% compared to 15% and at 48 hours following 
cisplatin treatment, p16-silenced cells showed 45% apoptosis compared to 17% in 
controls.  
 
TUNEL assay further confirmed that there were more apoptotic cells in p16 siRNA-
transfected cells than controls at 24 hours post-UV irradiation (Figure 4-9). Overall, we 
noticed a higher induction of apoptosis in cisplatin-treated p16-silenced cells compared 
to UV-irradiated p16-silenced cells (Figure 4-8), which may suggest that different 
modes of apoptosis induction are involved in response to UV- and cisplatin-induced 
DNA damage. Taken together, our data showed that cells which had reduced p16 
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Figure 4-9. TUNEL assay after UV-irradiation of p16-silenced SiHa cells. TUNEL 
assay confirms that p16 silencing enhanced UV-induced apoptosis in SiHa cells at 24h 
post-irradiation. Red fluorescent cells are positive for TUNEL staining. Cells were 
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4.2.9 Silencing of p16 in SiHa cervical cancer cells enhances p53 phosphorylation 
under UV- and cisplatin treatment.  
Under UV irradiation, increased p53 phosphorylation on serine 15, which is associated 
with stress-induced apoptosis (169), was observed in p16-silenced SiHa cells 
compared to control siRNA-treated cells (Figure 4-10). On the other hand, following 
cisplatin treatment, increased p53 phosphorylation on serine 46 was observed in p16-
silenced cells compared to control siRNA-treated cells (Figure 4-10). This strongly 
suggests that p53 was activated via different pathways in response to DNA damage by 
UV and cisplatin treatment. This is also consistent with our observation that the 
induction of apoptosis in p16-silenced cells after cisplatin treatment was higher 
compared to UV-induced apoptosis in p16-silenced cells (Figure 4-8). Our results 
indicate that the activation of p53 by phosphorylation associated with UV and cisplatin 
may regulate apoptosis in p16-silenced cells.  
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Figure 4-10. Silencing of p16 in SiHa cells enhances p53 phosphorylation under 
UV- and cisplatin treatment. After transfection with p16 siRNA or control siRNA, SiHa 
cells were then subjected to 100J/m2 UV-irradiation or cisplatin (20μM). Western blot 
analysis revealed UV-irradiation and cisplatin treatment specifically induced 
phosphorylation of p53 on serine 15 and serine 46, respectively. Data shown here are 
representative of at least 3 independent experiments. 
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4.2.10 Activation of p53 pathway, intrinsic and extrinsic apoptotic pathways in 
p16-silenced SiHa cells under UV irradiation.  
To determine apoptotic pathways induced by UV after p16 silencing, we compared the 
gene expression profiles of p16 siRNA or control siRNA-treated cells with or without UV 
irradiation using Affymetrix GeneChip analysis. We selected genes that were 
differentially expressed with respect to p16 silencing under UV treatment and focused 
on genes involved in DNA damage and apoptosis. Selected genes were further 
organized into known pathways and networks using Bibliosphere software (Genomatix, 
GmBH). These genes included p53 immediate downstream-regulated genes, anti-
apoptotic genes, as well as apoptotic genes involved in both the intrinsic mitochondrial 
apoptosis pathway and the extrinsic death receptor pathway (Table 4-1).  
 
Table 4-1 summarizes the changes in expression of 60 genes in the p16-silenced cells 
compared to control siRNA-treated cells at different time points after p16 or control 
siRNA transfection, with or without UV irradiation. This experiment was performed in 
duplicate. p16-silenced cells which were not subjected to UV-irradiation did not exhibit 
changes in the apoptotic genes. At 12 hours post-UV irradiation, the majority of genes 
involved in intrinsic and extrinsic apoptotic pathways remain unchanged. However, 24 
hours and 48 hours after UV-irradiation, p53 mRNA levels in p16-silenced cells 
increased by 2 to 3-fold compared to control siRNA-treated cells at 24 and 48 hours 
after UV-irradiation. Of particular interest were the well-known p53 DNA-damage target 
genes p21, PCNA, and GADD45A which were also up-regulated by 1.5 to 2-fold in UV-
irradiated, p16-silenced cells. The anti-apoptotic genes  BAG1, TIMP3, AKT1, MCL1 
and FAIM were down-regulated by 1.5 to 3-fold, while the apoptotic genes belonging to 
both the mitochondrial and death receptor pathways, such as caspases 8, Bcl family-
related genes, APAF1, FAS, FADD and TNFR-family genes were up-regulated by 2 to 
3-fold in UV-irradiated, p16-silenced cells (Table 4-1). These results show that UV-
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induced apoptosis of p16-silenced cells occurred through well established mitochondrial 
apoptosis and death receptor pathways, and was mediated to a certain extent through 
p53 and its target genes.  
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Table 4-1. Affymetrix Genechip analysis of expression changes in UV-induced apoptosis related 
genes in cells treated with p16 siRNA compared to control siRNA.  
p16 siRNA vs Control siRNA 
UV  without UV Affymetrix Probe ID Gene Title 
12h 24h 48h   24h 48h 72h 
Anti-Apoptosis        
202387_at BCL2-associated athanogene (BAG1) NC ⇓ ⇓  NC NC NC 
201150_s_at tissue inhibitor of metalloproteinase 3 (TIMP3) NC ⇓ ⇓  NC NC NC 
207163_s_at v-akt murine thymoma viral oncogene homolog 1 (AKT1) NC ⇓ ⇓  NC NC NC 
200798_x_at myeloid cell leukemia sequence 1 (BCL2-related) (MCL1) NC ⇓ ⇓  NC NC NC 
220643_s_at Fas apoptotic inhibitory molecule (FAIM) NC ⇓ ⇓   NC NC NC 
Apoptosis - p53 immediate downstream regulated genes        
211300_s_at tumor protein p53 (Li-Fraumeni syndrome) (TP53) ↑ ⇑ ⇑  ↑ ↑ ↑ 
203120_at tumor protein p53 binding protein, 2 (TP53BP2) NC ⇑ ↑  NC NC NC 
204531_s_at breast cancer 1, early onset (BRCA1) NC ⇑ ⇑  NC NC NC 
202981_x_at SIAH1 seven in absentia homolog 1 (Drosophila) (SIAH1) NC ↑ ↑  NC NC ↑ 
204947_at E2F transcription factor 1 (E2F1) ⇑ ⇑ ⇑  NC NC NC 
202284_s_at cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) NC ⇑ ⇑  NC NC NC 
209112_at cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) NC ⇑ ⇑  NC ⇑ NC 
205516_x_at CDKN1A interacting zinc finger protein 1 (CIZ1) NC ⇑ ⇑  NC NC NC 
208878_s_at p21 (CDKN1A)-activated kinase 2 (PAK2) NC ⇑ ⇑  NC NC NC 
33814_at p21(CDKN1A)-activated kinase 4 (PAK4) NC ⇑ ⇑  NC NC NC 
201202_at proliferating cell nuclear antigen (PCNA) NC ⇑ ⇑  NC NC NC 
203725_at GADD45A growth arrest and DNA-damage-inducible,alpha (GADD45A) NC ↑ ↑  NC NC NC 
Apoptosis - Mitochondrial (intrinsic) pathway        
209970_x_at caspase 1, apoptosis-related cysteine protease (CASP1) ⇑ ⇑ ⇑  NC NC NC 
208050_s_at caspase 2, apoptosis-related cysteine protease (CASP2) ⇑ ⇑ ⇑  NC NC NC 
210026_s_at caspase recruitment domain family, member 10 (CARD10) NC ⇑ ⇑  NC NC NC 
205263_at B-cell CLL/lymphoma 10 (BCL10) ⇑ ⇑ ⇑  NC NC NC 
206665_s_at BCL2-like 1 (BCL2L1) ⇑ ⇑ ⇑  NC NC NC 
222343_at BCL2-like 11 (apoptosis facilitator) (BCL2L11) ⇑ ⇑ ⇑  NC NC NC 
211725_s_at BH3 interacting domain death agonist (BID) NC ⇑ ⇑  NC NC NC 
202985_s_at BAG5 BCL2-associated athanogene 5 (BAG5) NC ⇑ ⇑  NC NC NC 
201101_s_at BCL2-associated transcription factor 1 (BCLAF1) NC ⇑ ⇑  NC NC NC 
218732_at Bcl-2 inhibitor of transcription (BIT1) NC ↑ ↑  NC NC NC 
209308_s_at BCL2/adenovirus E1B 19kDa interacting protein 2 (BNIP2) NC ⇑ ↑  NC NC NC 
201848_s_at BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3) NC ⇑ ⇑  NC NC NC 
208905_at cytochrome c, somatic (CYCS) ⇑ ⇑ ⇑  NC NC NC 
204859_s_at apoptotic protease activating factor (APAF1) NC ⇑ ⇑  NC NC NC 
219350_s_at diablo homolog (Drosophila) (DIABLO) NC ⇑ ⇑   NC NC NC 
Apoptosis - Death Receptor (extrinsic) pathway        
213373_s_at caspase 8, apoptosis-related cysteine protease (CASP8) NC ⇑ ⇑  NC NC NC 
209939_x_at CASP8 and FADD-like apoptosis regulator (CFLAR) NC ⇑ ⇑  NC NC NC 
215719_x_at Fas (TNF receptor superfamily, member 6) (FAS) NC ⇑ ⇑  NC NC NC 
202535_at Fas (TNFRSF6)-associated via death domain (FADD) NC ⇑ ⇑  NC NC NC 
208315_x_at TNF receptor-associated factor 3 (TRAF3) ⇑ ⇑ ⇑  NC NC NC 
202871_at TNF receptor-associated factor 4 (TRAF4) NC ↑ ⇑  NC NC NC 
204352_at TNF receptor-associated factor 5 (TRAF5) NC ⇑ ⇑  NC NC NC 
206907_at tumor necrosis factor (ligand) superfamily, member 9 (TNFSF9) NC ⇑ ⇑  NC NC NC 
209294_x_at tumor necrosis factor receptor superfamily, member 10b (TNFSF10B) NC ↑ ↑  NC NC NC 
210654_at tumor necrosis factor receptor superfamily, member 10d (TNFSF10D) NC ⇑ ↑  NC NC NC 
202643_s_at tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) NC ↑ ↑  NC NC NC 
218368_s_at tumor necrosis factor receptor superfamily, member 12A (TNFRSF12A) ⇑ ⇑ ⇑  NC NC NC 
201502_s_at NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha (NFKB1A) 
⇑ ⇑ ⇑   NC NC NC 
Apoptosis-Related Genes        
202731_at programmed cell death 4 (neoplastic transformation inhibitor) (PDCD4) NC ⇑ ⇑  NC NC NC 
203415_at programmed cell death 6 (PDCD6) NC ⇑ ↑  NC NC NC 
212422_at programmed cell death 11 (PDCD11) NC ⇑ ⇑  NC NC NC 
217746_s_at programmed cell death 6 interacting protein (PDCD6IP) NC ⇑ ⇑  NC NC NC 
201715_s_at apoptotic chromatin condensation inducer 1 (ACIN1) NC ⇑ ⇑  NC NC NC 
204004_at PRKC, apoptosis, WT1, regulator (PAWR) NC ⇑ ⇑  NC NC NC 
201095_at death-associated protein (DAP) NC ⇑ ⇑  NC NC NC 
208791_at clusterin (CLU) NC ⇑ ⇑  NC NC NC 
218350_s_at geminin, DNA replication inhibitor (GMNN) NC ⇑ ↑  NC NC NC 
220864_s_at cell death-regulatory protein GRIM19 (GRIM19) NC ⇑ ⇑  NC NC NC 
202431_s_at v-myc myelocytomatosis viral oncogene homolog (avian) (MYC) NC ⇑ ⇑  NC NC NC 
201710_at v-myb myeloblastosis viral oncogene homolog (avian)-like 2 (MYBL2) ⇑ ⇑ ⇑  NC NC NC 
203359_s_at c-myc binding protein (MYCBP) NC ⇑ ⇑  NC NC NC 
212099_at RHOB ras homolog gene family, member B (RHOB) ⇑ ⇑ ⇑  NC NC NC 
200607_s_at RAD21 RAD21 homolog (S. pombe) (RAD21) NC ↑ ↑   NC NC ↑ 
↑ denotes 1.5 to 2-fold significant increase, ⇑ or ⇓  denotes 2 to 3-fold significant (p<0.05) increase or decrease in signal 
intensity in p16 siRNA compared to control siRNA as computed by Affymetrix Microarray Analysis Suite (v5) change call 
statistical analysis algorithms. “NC” indicates no change in gene expression. 
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4.3.1 p16 up-regulation in cervical cancer 
The over-expression of p16 in cervical cancer has been reported by several groups 
using immunohistochemical studies (115, 120, 170). Wong et al. have also recently 
reported the up-regulation of p16 in Hong Kong cervical cancer patients by gene 
expression profiling using Affymetrix oligonucleotide arrays (157). Hence, our cDNA 
microarray analysis results confirm the up-regulation of p16 in cervical cancer 
patients in Singapore. Previously, it has been assumed that in cervical cancer cells, 
p16 is up-regulated due to a negative feedback loop between Rb and p16, whereby 
Rb is inactivated by HPV E7, thus leading to high p16 levels. As such, the up-
regulation of p16 has been deemed functionally redundant. However, this has not 
been proven conclusively. Since p16 is frequently mutated or absent in many other 
human cancers, it is of interest to us to investigate the implications of p16 up-
regulation in cervical cancer. Although the data presented here do not reveal the 
direct mechanism by which p16 is up-regulated, our results indicate the modulation of 
numerous genes when we silence p16 expression using siRNA. 
 
4.3.2 siRNA-mediated silencing of p16 in cervical cancer enhances DNA-
damage induced apoptosis through p53-mediated apoptotic pathways. 
Here we report that the silencing of p16 with siRNA in cervical cancer cells promotes 
apoptosis in cervical cancer cells when subjected to DNA-damaging agents.  It has 
been shown that p53 can directly activate both the intrinsic and extrinsic apoptotic 
pathways in response to DNA damage (171, 172).  Gene profiling experiments 
revealed the activation of genes involved in both the intrinsic mitochondrial and 
extrinsic death receptor-mediated apoptotic pathways, with the up-regulation of many 
p53 target genes following UV-irradiation and treatment with cisplatin in p16 siRNA-
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treated cervical cancer cells (Table 4-1).  This strongly suggests that the induction of 
apoptosis occurred via p53-mediated pathways. Furthermore we also observed the 
phosphorylation of p53 on serines 15 and 46 in UV-irradiated and cisplatin-treated 
cells respectively. These observations are consistent with reports suggesting that 
p53 is phosphorylated at different sites in different cell types under different forms of 
genotoxic stress (173, 174). Thus, this further confirms that p53 protein was activated 
in response to p16-silencing, which led to the activation of p53 downstream pathways 
to trigger apoptosis. We observed that the induction of apoptosis in p16 siRNA-
treated cells after cisplatin treatment was higher compared to UV-induced apoptosis 
in p16 siRNA-treated cells (Figure 4-5A), which may suggest that different modes of 
apoptosis induction are involved in response to UV- and cisplatin-induced DNA 
damage. This is further supported by reports that the phosphorylation of p53 on 
serine 46 is associated with more severe forms of DNA damage that triggers 
apoptosis via pathways different than those associated with phosphorylation of p53 
on other residues such as serine 15 (175).  
 
4.3.3 p16 expression in other cell types has protective role against DNA 
damage-induced apoptosis 
Interestingly, a study by Al-Mohanna et al. showed that p16-compromised 
osteosarcoma cells, and p16-null mouse embryo fibroblasts were more sensitive to 
UV- and cisplatin-induced apoptosis compared to p16-expressing cells, suggesting 
that p16 protects cells from undergoing apoptosis in response to UV and cisplatin 
treatment (176). This is agreement with our observations, which indicated that p16 
over-expression in cervical cancer cells prevents cells from undergoing DNA 
damage-induced apoptosis. However, this study showed that the anti-apoptotic role 
of p16 was mediated via the intrinsic mitochondrial pathway, namely through the pro-
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apoptotic Bax protein. This leads us to conclude that p16-mediated response to DNA 
damage-induced apoptosis may be cell type specific, and may or may not trigger the 
same pathways in different cell types. 
 
4.3.4 p16-silencing in cervical cancer cells in the absence of DNA damage-
inducing agents. 
From the present study, it is apparent that the activation of p53 in p16 siRNA-
silenced cells is different in the presence and absence of DNA damaging agents.  
When p16 was silenced with p16 siRNA, we observed the induction of p53 but not 
the phosphorylated form of p53.  However, when p16 silencing was coupled with 
DNA-damaging agents, p53 was specifically activated via phosphorylation of its 
serine residues to promote apoptosis. It is possible that p16-silencing affects 
pathways which are also involved in p53-mediated responses to DNA damage and 
that p16-silencing may contribute to the DNA damage stress response, directly 
resulting in activation of p53 by phosphorylation. We also observed that p16-silencing 
together with UV-irradiation resulted in decreased total p53 protein expression 
despite phosphorylation of p53 on serine 15. This could result from the degradation 
of p53 in cervical cancer cells after UV-irradiation but not cisplatin treatment, possibly 
mediated by mdm2, E6 or ubiquitin (177). This is further confirmed by our 
observation that p53 mRNA level was increased in p16 siRNA-treated cells 
compared to control siRNA treated cells under UV treatment (Lau et al., unpublished 
observation), and suggests that the decrease of p53 protein was not a result of 
modulation at the transcriptional level. However, induction of phosphorylation of p53 
by UV-irradiation is still intact. Our observation is similar to that of Lee et al., who 
observed the reduction of p53 by acetaminophen, but not etoposide and 5’ FU, 
despite phosphorylation of p53 on serines 15 and 37 (178). Furthermore, a recent 
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study has also shown that p16 inactivation leads to increased levels of p53 in human 
mammary epithelial cells, and that the sustained up-regulation of p53 may increase 
the selective pressure to inactivate p53 (179).  
 
On the other hand, up-regulation of p53 that occurs in p16-silenced cells is abolished 
under cisplatin treatment, nonetheless, phosphorylation of p53 on serine 46 was 
observed under cisplatin treatment. It is likely that p16-silencing is directly or 
indirectly involved in p53-mediated responses to DNA damage under stress such as 
UV-irradiation and cisplatin treatment, and may result in p53 activation through 
phosphorylation, without affecting p53 protein levels.  We propose that the responses 
triggered by silencing p16 alone, and in conjunction with DNA damage stress are 
different, and this may be an interesting avenue for future study in order to elucidate 
the relationship between p16 and p53 in cervical cancer cells. Overall, we have 
shown that p16 is not functionally redundant in cervical cancer cells and under 
certain circumstances, it could exert an anti-apoptotic role. 
 
In the absence of DNA damage, we found that p16-silenced cells had elevated levels 
of Rb, p53 and p21 protein, but did not undergo growth arrest or apoptosis that is 
commonly associated with p53 and p21 up-regulation (180, 181). This could be due 
to the effects of E6 and E7, both of which cooperate to bypass p53-induced G1 arrest 
and subsequently drive cell cycle progression in cervical cancer cells (75, 182, 183). 
This statement can be further supported by evidence that when both HPV16 E6 and 
E7 are repressed, cervical cells are able to undergo senescence or apoptosis in 
response to DNA damage (184). Although we observed a down-regulation of E7 
mRNA after p16-silencing, we did not detect any alteration in E6 mRNA expression. 
Based on the observations from this study, we propose that induction of p53 after 
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p16-silencing occurs independently of E6. Since SiHa and Cas Ki cells express wild-
type p53 (185), we hypothesize that when p53 levels increase above a “basal 
threshold” in these cells, such as in the case of p16-silencing, p53-mediated 
pathways are activated.  However, it has also been earlier reported that E6 and E7 
are expressed from a bicistronic mRNA (186).  In the light of these data, further study 
is required to fully dissect the differential effect of p16-silencing on E6 and E7 
expression.   
 
4.3.5 p16-silencing in cervical cancer is able to trigger p53 and RB pathways. 
p16 knockdown in conjunction with DNA-damage triggers the p53 and RB pathways, 
sensitizing the cells to apoptosis. This confirms that although HPV16 E6 and E7 
inactivate p53 and RB respectively in cervical cancer cells, these cells still express 
basal levels of p53 and Rb proteins, leaving both the RB and p53 tumour suppressor 
pathways functionally intact and susceptible to re-activation by appropriate stress 
signals (187, 188). It has also been shown that p53-dependent G1 arrest involves Rb, 
thus linking these two tumour suppressor pathways in mediating cell cycle 
progression and arrest (76). As a result of p16 suppression using siRNA, we 
observed the up-regulation of Rb, p53 and p21, all of which are crucial in tumour 
suppression. Therefore, the perturbation of the feedback loop that normally maintains 
Rb at low levels and p16 at high levels in cervical cancer cells is a major factor in 
driving the cell toward apoptosis, as it is able to regulate Rb, p53 and p21. However, 
further studies are required to conclusively elucidate the underlying molecular 
mechanism. Nevertheless, the ability of p16 to influence RB and p53 tumour 
suppressor pathways despite HPV16 infection offers new avenues to develop novel 
therapeutic strategies.  Several studies have described the use of viral- and RNAi-
mediated approaches to repress E6 and E7 to induce senescence or apoptosis (189-
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191).  Our findings suggest that silencing of p16 in conjunction with chemotherapy 
and radiotherapy could potentially be an effective treatment for cervical cancer. 
 
4.4 Conclusion and future studies 
The data from our study show that siRNA-mediated silencing of p16 in cervical 
cancer augments DNA-damage induced apoptosis via p53-mediated activation of 
intrinsic and extrinsic apoptotic pathways. More importantly, p16 up-regulation in 
cervical cancer is not functionally redundant; on the contrary, p16 plays an important 
role in cervical carcinogenesis by preventing DNA damage-induced apoptosis. 
Consequently, it would prove useful to further elucidate the underlying molecular 
pathways by which p16 is able to trigger apoptosis through the intrinsic and extrinsic 
apoptotic pathways. In addition, our studies described here were performed in cell 
lines in vitro. It would be useful to extend this study to a xenograft model using an 
inducible p16-specific shRNA construct, to provide further evidence to support the 
hypothesis that down-regulation of p16 in cervical cancer-derived cell lines would 
provide therapeutic benefit.
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NDRG1 has been implicated in a variety of biological and physiological functions in 
normal and neoplastic cells. We have detected the over-expression of NDRG1 in 30 
cervical cancer tissues compared to 20 non-tumourous tissues and 12 normal 
cervical tissues. To clarify the functional role of NDRG1 in cervical cancer, RNAi 
functional studies were employed to specifically inhibit NDRG1 expression in cervical 
cancer cells. We observed that NDRG1 silencing resulted in G1 cell cycle arrest, 
accompanied by a concomitant increase in p53 and p21 levels. Sustained 
suppression of NDRG1 expression for 5 days led to induction of a senescence-like 
phenotype. Up-regulation of endogenous NDRG1 levels using cobalt chloride, a 
known inducer of NDRG1 was able to abolish the senescent-like phenotype. 
Furthermore, the senescence-like phenotype induced by NDRG1 silencing was 
reversed by co-transfection of NDRG1 and p53 siRNA, indicating that induction of the 
senescence-like phenotype is mediated by p53. However, inhibition of p53 
expression after onset of the senescence-like phenotype was not able to reverse the 
phenotype, suggesting that p53 was required for induction but not maintenance of 
this senescence-like phenotype. These data reveal for the first time the up-regulation 
of NDRG1 in cervical cancer, and the observation that NDRG1 silencing results in 
cell cycle arrest highlights a novel role of NDRG1 in cervical carcinogenesis, as well 
as providing new avenues for anti-cancer therapy.  
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5.2 Results 
5.2.1 Significant up-regulation of NDRG1 gene expression in cervical cancer 
Amongst the genes over-expressed in cervical cancer, we have detected significant 
up-regulation of NDRG1 in 30 cervical cancer tissues compared to 20 non-tumourous 
tissues (p<0.01) and 12 normal cervical tissues (p<0.001; Figure 5-1A). A separate 
set of 8 tumour, 8 non-tumourous and 8 normal cervical tissues were employed to 
perform reverse transcription-quantitative real time PCR analysis, which confirmed 
100-fold and 180-fold NDRG1 up-regulation in cervical carcinoma compared to both 














































Figure 5-1. Significant up-regulation of NDRG1 gene expression in cervical 
cancer. Gene expression of NDRG1 in normal (N), non-tumourous (NT) or tumour (T) 
samples as determined by (A) cDNA library screening using spotted cDNA microarrays 
and (B) real time PCR analysis. Sample size is indicated by ‘n’. Bars represent median 
values while asterisks denote significant difference (p<0.05) using one-way ANOVA with 
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5.2.2 Detection of endogenous NDRG1 in cervical cancer cells  
Since NDRG1 was over-expressed in cervical tumour tissue compared to non-
tumourous and normal cervical tissue, we then checked the endogenous level of 
NDRG1 in two cervical cancer cell lines, SiHa and Cas Ki. Both cells lines showed a 
specific NDRG1 protein band at 43 kD by Western blot analysis (Figure 5-2A) and a 









Figure 5-2. NDRG1 endogenous expression in SiHa and Cas Ki cell lines. (A) 
Western blot and (B) Northern blot analysis showed specific NDRG1 expression in 





5.2.3 NDRG1 siRNA specifically inhibits expression of NDRG1 in cervical 
cancer cells  
To study the functional role of NDRG1 in the development of cervical cancer, we 
employed short interfering RNAs (siRNAs) to silence NDRG1 gene expression in 
these cervical cancer cell lines and monitor the biological changes. It has been 
suggested that using a combination of siRNA sequences can minimize possible non-
specific off-target effects caused by a single siRNA sequence alone, hence we 
combined and transfected two independent sequences of NDRG1 siRNAs (Invitrogen) 
at 50nM and 100nM final concentrations to determine the optimal concentration for 
achieving NDRG1 silencing. We found that 100nM NDRG1 siRNAs had a greater 
suppression effect on NDRG1 protein expression as compared to 50nM of siRNA 
(Figure 5-3).  
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Figure 5-3. Optimization of siRNA-mediated silencing of NDRG1 protein 
expression in cervical cancer cells. A combination of two independent sequence 
of NDRG1 siRNAs at a final concentration of 50nM or 100nM was transfected into 
SiHa and Cas Ki cells. After 24h, cells were harvested and the expression of NDRG1 
was monitored by Western blot analysis. “Nil” indicates cells without any treatment. 
 
 
We obtained significant down-regulation of NDRG1 protein levels in SiHa cells using 
NDRG1 siRNA compared to control siRNA (Figure 5-4A). We achieved 55% 
reduction in NDRG1 mRNA expression resulting in significant silencing of NDRG1 
protein expression 48 hours after transfection with NDRG1 siRNAs in SiHa cells 
(Figure 5-4B). Similar down-regulation of NDRG1 protein and mRNA level was 
observed in Ca Ski cells (Figure 5-4A and 5-4B). The control siRNA sequence had 
no silencing effect on NDRG1 mRNA or protein, thus confirming that the NDRG1 
siRNAs used were sequence-specific. Furthermore, sustained suppression of 
NDRG1 protein expression was observed for up to at least 72 hours following the 
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Figure 5-4. NDRG1 siRNA specifically inhibits expression of NDRG1. (A) The 
expression of NDRG1 was determined by Western blot in SiHa and Cas Ki cells 48h 
after transfection with mixed NDRG1 or control siRNA. (B) Real-time PCR 
quantitation of mRNA levels in SiHa and Cas Ki cells after NDRG1 siRNA silencing. 
The relative mRNA levels were determined in relation to control siRNA, which was 





























Figure 5-5. Time course of NDRG1 siRNA effects on NDRG1 protein levels. SiHa 
cells were transfected with 100nM of mixed NDRG1 siRNA or control siRNA (labeled 
as Nil). Cells were harvested at 24h, 48h and 72h. The expression of NDRG1 was 





Section 3 – Results and Discussion 
 
5.2.4 NDRG1 silencing results in decreased cell proliferation in cervical cancer 
cells  
To assess the effect of NDRG1 silencing on cell growth, we monitored cell 
proliferation rates using alamarBlueTM in SiHa cells transfected with NDRG1 or 
control siRNA for 5 days. We observed a significant decrease in proliferation rate for 
NDRG1-silenced SiHa cells compared to control siRNA-treated cells (Figure 5-6). 
Complete growth arrest was detected in SiHa cells by day 4 following NDRG1 siRNA 
 
treatment.  
igure 5-6 NDRG1 silencing results in decreased cell proliferation rate in 
cervical cancer cells and leads to growth arrest. The growth curves of SiHa cells 


























transfected with NDRG1 or control siRNA were determined using alamarBlueTM 
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Using BrdU incorporation assay, we further confirmed whether the growth arrest 
observed at day 4 post-transfection of siRNA was caused by the inhibition of 
proliferation rate. As shown by Figure 5-7, SiHa cells transfected with NDRG1 siRNA 
had a lower percentage of S-phase proliferating cells (13%) compared to control 
siRNA-treated cells (28%). Cas Ki cells transfected with NDRG1 siRNA showed 
similar results, with S-phase cells at 16% compared to 27% in control siRNA-
transfected cells. Taken together, this indicated that suppression of NDRG1 




Figure 5-7 NDRG1 siRNA-induced growth arrest is related to inhibition of cell 
proliferation. BrdU incorporation assay was used to determine percentage of SiHa 
and Cas Ki cells in S-phase of cell cycle 48 hours after transfection with NDRG1 or 
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5.2.5 Inhibition of cell growth induced by NDRG1 silencing in cervical cancer 
cells is related to G1 cell cycle arrest 
To further analyze the effect of NDRG1 silencing on the cell cycle, flow cytometric 
analysis with PI staining was performed on SiHa and Cas Ki cells 48 hours after 
transfection with NDRG1 or control siRNA. We found that NDRG1-silenced SiHa 
cells underwent G1 growth arrest, with a significantly higher G1 cell population of 
82% compared to 66% in control siRNA-treated cells. S-phase populations were 12% 
and 22% in NDRG1 and control siRNA-treated cells respectively, and G2/M-phase 
cell populations were 6% and 13% in NDRG1 and control siRNA-treated cells 
respectively (Figure 5-8). Cas Ki cells also showed growth arrest at G1-phase, with 
70% of NDRG1-silenced cells in G1-phase, and 22% and 8% in S- and G2/M-phase 
respectively, whereas control siRNA-treated cells showed G1, S and G2/M-phase 
cell populations of 60%, 31% and 11% respectively. At the same time, we did not 
observe any apoptotic cells as seen by a lack of sub-G1 phase cell populations. Our 
data therefore demonstrate that the inhibition of cell proliferation by NDRG1 silencing 

















Figure 5-8. Inhibition of cell growth induced by NDRG1 silencing in cervical 
cancer cells is related to G1 cell cycle arrest. Cell cycle profile of SiHa and Cas Ki 
cells transfected with NDRG1 or control siRNA was determined after 48 hours by 
FACS analysis of propidium iodide staining. Data shown are representative of 3 






5.2.6 G1 cell cycle arrest induced by NDRG1 silencing in cervical cancer cells 
is accompanied by altered expression of growth-related genes 
In order to correlate gene expression changes to G1 cell cycle arrest observed in 
NDRG1-silenced cervical cancer cells, we applied Affymetrix GeneChip analysis to 
study the gene expression profile of SiHa cells which had been transfected with 
NDRG1 siRNA or control siRNA for 48 hours. This experiment was performed twice 
to ensure reproducibility. Genes related to cell growth and proliferation that were 
statistically differentially expressed between NDRG1 siRNA-treated and control-
treated SiHa cells were retrieved. In total, we observed 52 differentially regulated 
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genes, 31 were up-regulated and 21 were down-regulated in NDRG1-silenced cells 
respectively (Table 5-1). The up-regulated genes included p53, p53-activated protein 
1 (TP53AP1), p53 binding protein 1 (TP53BP1), p53 inducible protein 3 (TP53I3), 
MDM2, retinoblastoma-like 1, IGFBP3 and CHES1, which are related to cell cycle 
progression and arrest. Other up-regulated genes included matrix metalloproteinases 
13 and 14 (MMP13, 14), as well as phosphatase and tensin homologue (PTEN), jun 
D proto-oncogene (JUND), and protective protein for β-galactosidase (PPGB).  
 
On the other hand, matrix metalloproteinases 1, 2 and 3 (MMP1,2,3), as well as 
tissue inhibitor of metalloproteinases 1, 2 and 3 (TIMP1,2,3) were down-regulated, 
and vascular endothelial growth factor (VEGF), all of which are known to regulate 
cellular growth.  
 
These data show the alteration in growth-related genes as a result of NDRG1-
silencing in SiHa cervical cancer cells, and further confirmed that NDRG1-silenced 
cells were growth inhibited and undergoing G1 cell cycle arrest as shown earlier. 
Interestingly, many of these genes are involved in cellular senescence, such as 
proliferating cell nuclear antigen (PCNA), T-box 2 (Tbx2), minichromosome 
maintenance deficient 3 (MCM3), dihydrofolate reductase (DHFR), inhibitor of DNA 
binding 1/2/3 (ID1/2/3), matrix metalloproteinases (MMP1-19), TIMP1,2,3, connective 
tissue growth factor (CTGF), promyelocytic leukemia (PML), KRAS, p16, p21, p27, 
cyclin D1, E2F1, DP-1 and retinoblastoma like 1 (RBL1) (192-195). As a result, this 
prompted us to investigate if cell cycle arrest induced by NDRG1-silencing was 
associated with senescence. 
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201715_s_at apoptotic chromatin condensation inducer 1 ACIN1 1.59
200920_s_at B-cell translocation gene 1, anti-proliferative BTG1 2.47
212563_at block of proliferation 1 BOP1 2.24
201236_s_at BTG family, member 2 BTG2 3.22
213275_x_at cathepsin B CTSB 2.94
205022_s_at checkpoint suppressor 1 CHES1 2.63
208712_at cyclin D1 CCND1 8.38
202769_at cyclin G2 CCNG2 1.85
213348_at cyclin-dependent kinase inhibitor 1C (p57) CDKN1C 2.53
209644_x_at cyclin-dependent kinase inhibitor 2A (p16) CDKN2A 1.78
204159_at cyclin-dependent kinase inhibitor 2C (p18) CDKN2C 1.83
48808_at dihydrofolate reductase DHFR 2.36
204921_at grow th arrest-specific 8 GAS8 2.09
210350_x_at inhibitor of grow th family, member 1 ING1 1.97
210095_s_at insulin-like grow th factor binding protein 3 IGFBP3 2.57
209784_s_at jagged 2 JAG2 2.42
214326_x_at jun D proto-oncogene JUND 2.88
217279_x_at matrix metalloproteinase 14 MMP14 2.64
203365_s_at matrix metalloproteinase 15 MMP15 5.32
201555_at MCM3 minichromosome maintenance deficient 3 MCM3 1.90
217373_x_at Mdm2 MDM2 1.52
211711_s_at phosphatase and tensin homolog PTEN 1.86
209640_at promyelocytic leukemia PML 2.51
200661_at protective protein for beta-galactosidase (galactosialidosis) / cathepsin A PPGB 1.82
205296_at retinoblastoma-like 1 (RBL1/p107) RBL1 2.86
219682_s_at T-box 3 TBX3 1.73
209917_s_at TP53 activated protein 1 TP53AP1 2.15
212330_at transcription factor Dp-1 TFDP1 2.56
201746_at tumor protein p53 (Li-Fraumeni syndrome) TP53 1.80
203050_at tumor protein p53 binding protein, 1 TP53BP1 1.93
210609_s_at tumor protein p53 inducible protein 3 TP53I3 1.60
Downregulated Genes
210916_s_at CD44 antigen CD44 0.20
210559_s_at cell division cycle 2, G1 to S and G2 to M CDC2 0.54
213523_at cyclin E1 CCNE1 0.28
211804_s_at cyclin-dependent kinase 2 CDK2 0.43
203957_at E2F transcription factor 6 E2F6 0.48
207826_s_at inhibitor of DNA binding 3 ID3 0.13
201473_at jun B proto-oncogene JUNB 0.50
203362_s_at MAD2 mitotic arrest deficient-like 1 (yeast) MAD2L1 0.27
204475_at matrix metalloproteinase 1 MMP1 0.19
201069_at matrix metalloproteinase 2 MMP2 0.30
205828_at matrix metalloproteinase 3 MMP3 0.05
206234_s_at matrix metalloproteinase 17 MMP17 0.15
201202_at proliferating cell nuclear antigen PCNA 0.73
201666_at tissue inhibitor of metalloproteinase 1 TIMP1 0.45
203167_at tissue inhibitor of metalloproteinase 2 TIMP2 0.65
201149_s_at tissue inhibitor of metalloproteinase 3 TIMP3 0.37
211527_x_at vascular endothelial grow th factor VEGF 0.27
201328_at v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) ETS2 0.31
201466_s_at v-jun sarcoma virus 17 oncogene homolog (avian) JUN 0.55
204009_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog KRAS 0.28
Table 5-1. Affymetrix Genechip analysis of gene expression changes in growth-related genes in 
NDRG1-silenced cervical cancer cells
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5.2.7 NDRG1 silencing is associated with senescence-like phenotype in 
cervical cancer cells 
We performed staining for β-galactosidase activity at pH 6.0 (SA-β-Gal assay), a 
widely used positive marker of cellular senescence (196), in cells after a prolonged 5-
day period of NDRG1 suppression by siRNA. We observed SA-β-Gal positive 
staining in NDRG1-silenced cells compared to control siRNA-treated cells (Figure 5-
9A). We counted SA-β-Gal positive cells and total cell number in 10 fields for each 
treatment and found a significantly higher percentage of 80% SA-β-Gal positive cells 
in NDRG1-silenced cells compared to 20% SA-β-Gal positive control cells in both 
SiHa and Cas Ki cell lines (Figure 5-9B), suggesting that the NDRG1-silenced cells 





Figure 5-9. NDRG1 silencing is associated with senescence-like phenotype in 
cervical cancer cells. (A) SiHa and Cas Ki cells transfected with NDRG1 or control 
siRNA were maintained in culture for 5 days before performing SA-β-Gal assay. (B) 
The number of blue (positive) cells was expressed as a percentage of the total cell 
number in each field. 20 fields were counted using a Nikon Eclipse TS100 
microscope at 40x magnification for all cells. 
 110
Section 3 – Results and Discussion 
 
5.2.8 NDRG1 siRNA-induced senescence-like growth arrest can be restored by 
up-regulation of endogenous NDRG1 upon cobalt chloride treatment 
To further confirm that the senescence-like phenotype in these cervical cancer cells 
is related to NDRG1 silencing but not other unexpected and non-specific effects of 
NDRG1 siRNA, we incubated NDRG1 and control siRNA-treated cells with cobalt 
chloride (CoCl2), a hypoxia mimetic that has been well-characterized as an inducer of 
NDRG1 expression. We observed that in the presence of cobalt chloride, inhibition of 
NDRG1 expression using the same amount of NDRG1 siRNA was diminished and 
NDRG1 protein levels increased slightly (Fig 5-10B). Interestingly, the restoration of 
NDRG1 expression by concomitant treatment with cobalt chloride was shown to 
abolish the senescence-like phenotype induced by NDRG1 siRNA (Fig 5-10A). This 
showed that up-regulation of NDRG1 by CoCl2 despite treatment with NDRG1 siRNA 
was sufficient to prevent induction of senescence-like phenotype observed earlier in 




NDRG1 siRNA:    +    -- +    -- +    -- +    --
Control siRNA:    -- +   -- +     -- +   -- +








Figure 5-10.  NDRG1 siRNA-induced senescence-like growth arrest can be 
restored by up-regulation of endogenous NDRG1 upon cobalt chloride 
treatment. SiHa and Cas Ki cells were transfected with mixed NDRG1 or control 
siRNA for 24h then treated with cobalt chloride to induce endogenous NDRG1 for 
another 4 days before performing (A) SA-β-Gal assay and (B)  Western blot analysis.  
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5.2.9 Senescence-like phenotype mediated by NDRG1 silencing is associated 
with up-regulation of p53 and p21 and can be attenuated by p53 silencing 
We found that siRNA-mediated silencing of NDRG1 was accompanied by an up-
regulation of p53, and concomitant increase in its downstream target p21 (Figure 5-
11A), suggesting that the p53 pathway may be involved in the induction of a 
senescence-like phenotype. To investigate the role of p53 in induction of a 
senescence-like phenotype after NDRG1-silencing, SiHa and Cas Ki cells were 
transfected with p53 siRNA alone or co-transfected with NDRG1 and p53 siRNA, and 
monitored for 5 days for SA-β-Gal activity. More importantly, we observed that cells 
with NDRG1-silencing as well as p53-silencing showed decrease of NDRG1, p53 
and p21 protein expression (Figure 5-11A), effectively abolishing the senescence-like 
phenotype we detected earlier in NDRG1-silenced cells (Figure 5-9). This strongly 
suggests that induction of a senescence-like response following NDRG1-silencing is 
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Figure 5-11. Senescence-like phenotype mediated by NDRG1 silencing is 
associated with up-regulation of p53 and p21 and can be attenuated by p53 
silencing. SiHa and Cas Ki cells were treated with siRNA for 5 days. (A) Western 
blot analysis was performed using total cell lysate of SiHa cells to determine the 
protein expression of NDRG1, p53 and p21. (B) Cells were stained for SA-β-Gal to 




5.2.10 Senescence-like phenotype at day 5 post-transfection induced by 
NDRG1 silencing is not reversible by subsequent p53 inhibition or release of 
NDRG1 suppression 
To investigate whether p53 silencing would be able to reverse the NDRG1 silencing 
induced senescence-like phenotype after the onset, we transfected SiHa and Cas Ki 
cells with NDRG1 siRNA for 5 days, following which they were co-transfected with 
NDRG1 and p53 siRNA or control siRNA alone and incubated for a further 4 days. 
We found that cells which had been treated with NDRG1 siRNA for 5 days to induce 
senescence-like phenotype were still positive for SA-β-Gal activity despite 
subsequent p53 silencing (Figure 5-12A and 5-12B).  This data indicates that 
following onset of a senescence-like phenotype, p53 inhibition is no longer able to 
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reverse it, suggesting that p53 is required for induction of senescence, but is not 
essential for maintenance of the phenotype. We also found that after the observation 
of a senescence-like phenotype in NDRG1-silenced cells, release of transient 
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p53 siRNA (Day 5)
 
Figure 5-12. Senescence at day 5 post-transfection induced by NDRG1 
silencing is not reversible by subsequent p53 inhibition or release of NDRG1 
suppression. SiHa or Cas Ki cells were treated with NDRG1 or control siRNA for 5 
days to induce senescence following which they were co-transfected with NDRG1 
and p53 siRNA or control siRNA and incubated for a further 4 days. (A) SA-β-Gal 
staining showed that senescence was not reversible by p53 inhibition after day 5. (B) 
Western blot analysis was performed using total cell lysate of SiHa cells to determine 
the protein expression of NDRG1, p53 and p21. Data shown represent 2 
independent experiments. 
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5.2.11 Ectopic NDRG1 over-expression in SiHa cervical cancer cells  
According to our study, silencing of NDRG1 can result in senescence-like G1 arrest. 
However, it is unknown whether NDRG1 may play a role in cell proliferation or inhibit 
cellular senescence. We thus ectopically over-expressed NDRG1 in cells and 
monitored its biological effects. SiHa cells were transfected for 24 hours with a 
pcDNA3-NDRG1-FLAG plasmid construct, and western blot analysis using anti-
NDRG1 antibody (Santa Cruz) showed the ectopic expression of NDRG1-FLAG as 
well as endogenous NDRG1 protein, distinguishable by a slightly slower migrating 
band for NDRG1-FLAG protein (Figure 5-13A). We were also able to detect ectopic 
NDRG1 protein using anti-FLAG antibody (Stratagene). Hence, we were able to 
independently determine the expression of both endogenous and ectopic NDRG1 
proteins, and our data show that ectopic over-expression of NDRG1 protein did not 
affect endogenous NDRG1 protein levels. In order to study the effects of ectopic 
over-expression of NDRG1, we stably transfected SiHa cells and generated three 
stable clones containing pcDNA3-NDRG1-FLAG as well as three control stable 
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Figure 5-13. Ectopic over-expression of NDRG1 in SiHa cells transfected with 
pcDNA3-NDRG1-FLAG or pcDNA3 for 24 hours. Western blot analysis shows the 
expression of both endogenous and ectopic NDRG1 (A) in SiHa cells after transient 
transfection of pcDNA3-NDRG1-FLAG construct and (B) in stably transfected SiHa 




5.2.12 Ectopic NDRG1 over-expression results in increased proliferation rate in 
SiHa cervical cancer cells 
We monitored the stable SiHa cell lines over a period of 4 days using alamarBlueTM 
proliferation assay and found that the three stable cell lines over-expressing ectopic 
NDRG1 showed increased cell proliferation rate compared to the three control 
pcDNA3 vector-transfected stable cell lines (Figure 5-14).  Overall, this suggests that 
ectopic over-expression of NDRG1 in SiHa cervical cancer cells leads to increased 
cell growth and proliferation. 
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Figure 5-14. Over-expression of ectopic NDRG1 in SiHa stable cell lines results 
in increased cell proliferation rate. alamarBlueTM proliferation assay over a period 
of 4 days shows an increase in cell proliferation in stable SiHa cell lines ectopically 
expressing NDRG1 compared to stable cell lines containing pcDNA3 construct alone. 
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5.3 Discussion 
5.3.1 Up-regulation of NDRG1 in cervical cancer and its implications 
We report for the first time the significant up-regulation of NDRG1 gene expression in 
cervical cancer compared to non-cancerous and normal cervical tissues. NDRG1 has 
not been previously implicated in cervical cancer, and it is of interest to note that 
NDRG1 has been widely reported as a down-regulated gene in human prostate, 
colon and breast cancers, and has been regarded as a metastasis suppressor (121, 
139, 147, 148). The induction of NDRG1 at both the RNA and protein level under 
hypoxic conditions has been well-characterized (125, 136). Hence, the up-regulation 
of NDRG1 in cervical cancer might be linked to tumour hypoxia, a common feature of 
solid tumours that results from inadequate oxygen supply to the tumour. Cervical 
tumours frequently develop hypoxic regions, and studies have shown that there is a 
correlation between tumour hypoxia and malignant progression in cervical cancer, 
hence hypoxia is a powerful, independent prognostic factor in cervical cancer (51, 
197-199). Hypoxia in cervical tumours poses a significant therapeutic problem as it 
increases resistance to radiation and chemotherapy (198, 200-202), and leads to 
increased tumour invasiveness and metastasis (52, 197). The hypoxia response is 
largely mediated by hypoxia inducible factor 1α (HIF-1α), and HIF-1α expression has 
been suggested to be an intrinsic marker for hypoxia in cervical cancer (202, 203). 
Moreover, numerous clinical studies have shown HIF-1α to be a prognostic indicator 
for unfavourable outcome and treatment resistance in cervical cancer (203-206). In 
addition, hypoxic induction of NDRG1 expression is reportedly dependent on HIF-1α 
(136, 137), and in agreement with these  findings, it is likely that over-expression of 
NDRG1 in cervical cancer could be a consequence of hypoxia-regulated pathways, 
and NDRG1 could serve as a marker for hypoxia. In order to correlate NDRG1 up-
regulation and hypoxia in cervical cancer, further studies need to be conducted with 
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well-documented clinical information and patient samples. In addition, whether 
induction of NDRG1 may contribute to tumourigenesis deserves to be further 
investigated. 
 
5.3.2 NDRG1-silencing and induction of G1 cell cycle arrest and senescence-
like phenotype 
We demonstrated that NDRG1 siRNA-mediated inhibition of cell growth in cervical 
cancer cells resulted in cell cycle arrest at G1 phase. Furthermore, prolonged 
suppression of NDRG1 subsequently induced a senescence-like phenotype, as 
shown by positive staining of SA-β-gal, an established marker of senescence (196). 
Cellular senescence was originally defined as a permanent replicative arrest 
occurring in normal cells after a finite number of cell divisions (207), and it is now 
understood that replicative senescence occurs as a result of progressive telomere 
shortening, leading to permanent growth arrest and a defined lifespan (208). Since 
telomeric changes in cells undergoing replicative senescence are highly similar to 
changes observed during DNA damage, it was not surprising to observe that DNA 
damage-induced growth arrest was phenotypically indistinguishable from replicative 
senescence (209, 210). Moreover, growth arrest of senescent cells is initiated with 
the activation of p53, and induction of p21 levels (211, 212). It has also been shown 
that p16 is also up-regulated during human fibroblast senescence, and is required for 
terminal stages of growth arrest in senescence (213). Although the pathways and 
mechanisms mediating senescence in cancer cells are less well-characterized, there 
is evidence that DNA damage is able to induce senescence in tumour cells 
expressing wild-type p53, and that p53 and p21 play a central role in onset of 
senescence, while p16 may be involved in maintaining senescence. Our data (Table 
5-1) show that p16 was indeed up-regulated in association with the growth arrest 
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observed after NDRG1 silencing (Figure 5-8), and may subsequently be involved in 
mediating a senescence-like phenotype.  
 
Importantly, we also observed that NDRG1 siRNA-mediated G1 arrest and a 
senescence-like phenotype in cervical cancer cells was associated with the 
concurrent up-regulation of p53 and its downstream target gene, p21, hence, this 
strongly suggests that this phenotype is mediated through a p53-dependent pathway. 
In addition, our data demonstrate that simultaneous silencing of both NDRG1 and 
p53 in cervical cancer cells could abolish the senescence-like phenotype, further 
confirming the essential role of p53 in the induction of a senescence-like phenotype 
(211, 214). On the other hand, after the onset of senescence-like phenotype, p53 
silencing alone was not able to reverse the senescent-like phenotype, suggesting 
that p53 is not required for maintaining the senescence-like phenotype. This is in 
agreement with previous reports that p53 is crucial for the initiation but not the 
maintenance of a growth arrest and senescent phenotype (102, 193, 195, 215).  
 
5.3.3 NDRG1 may induce p53 or vice versa 
In normal cells, cellular senescence is considered an important tumour-suppressive 
mechanism for preventing uncontrolled cell proliferation and malignant transformation 
(216-219). As previously mentioned, recent studies have shown that cancer cells can 
also enter a senescence-like state in response to DNA damaging agents (155, 220). 
The role that NDRG1-silencing plays in triggering a senescence-like phenotype in 
cervical cancer cells is a novel one, and it is unclear how this response is executed. It 
is plausible that NDRG1 up-regulation prevents the activation of cell cycle inhibitory 
pathways such as p53 and RB that regulate growth arrest and senescence, and 
thereby contributes to tumourigenesis. In this aspect, further detailed gene 
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expression studies would reveal more about the role of NDRG1 in the network of 
genes which initiate growth arrest and senescence. It is of interest to note that 
NDRG1 may induce p53 in a yet unknown pathway or network which can mediate 
cell cycle progression and inhibition. So far, there has been no known evidence of 
p53 regulation by NDRG1. However, there have been studies showing that NDRG1 
is regulated by p53 in response to DNA damaging agents, and that transcriptional 
activation of NDRG1 occurs via a p53-binding site on the NDRG1 promoter region 
(123). In addition, it has been reported that NDRG1 functions as a mitotic checkpoint 
gene ensuring p53-mediated cell division fidelity, specifically, by rescuing p53-null 
cells from mitotic arrest due to spindle damage (187, 188). Nonetheless, our present 
study showed that silencing of NDRG1 did slightly increase p53 levels, but p53 
silencing did not have an effect on NDRG1 levels. In cervical cancer cells, p53 is 
inactivated by the E6 protein of high-risk human papillomavirus types, but the p53 
pathway is functionally intact, with wild-type p53 expressed at basal levels in the cells 
(121, 123, 136, 139, 147). Our findings further confirm that p53 can still exert its 
effects in response to the appropriate signals, and suppression of NDRG1 with 
siRNA apparently triggers p53 to induce a senescence-like response. We have 
shown that NDRG1 may possibly regulate p53, and since p53 is an important 
mediator of cell cycle arrest, senescence or apoptosis in response to stress signals, 
this is a promising area of study to further develop anti-cancer strategies in cervical 
cancer.  
 
5.3.4 NDRG1 and p16: synergistic roles in tumourigenesis? 
This chapter has discussed NDRG1 up-regulation in cervical cancer cells, which 
contributes to evasion of growth arrest and senescence in cervical cancer cells, 
whereas Chapter 4 has highlighted the role of p16 up-regulation in preventing cells 
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from undergoing DNA damage-induced apoptosis. High levels of NDRG1 and p16 in 
cervical cancer cells prevent growth arrest and apoptosis respectively, thus we 
postulate that NDRG1 and p16 may have a synergistic effect in cervical 
carcinogenesis. At the same time, silencing of NDRG1 expression resulted in an 
increase in p16 levels, which suggests that there is an indirect relationship between 
both genes, or cross-talk in pathways mediated by both genes. However, at this 
juncture we do not have enough evidence to support this claim, and further work 
must be done to prove any underlying mechanisms. It would be interesting to 
investigate whether simultaneous transfection of both p16 as well as NDRG1 siRNA 
would result in more efficient growth arrest occurring in a shorter time, or increased 
apoptotic induction in cervical cancer cells.  
 
5.3.5 NDRG1 as a potential prognostic marker in cervical cancer 
While NDRG1 has been found to be differentially regulated in many human cancers, 
its role in cancer is still controversial, as some studies show NDRG1 to be down-
regulated and to suppress growth and metastasis, whilst others have reported that it 
is over-expressed in many human cancers. We have found that NDRG1 is up-
regulated in cervical cancer, and that its over-expression may play a role in cell cycle 
progression of cancer cells, thereby contributing to the malignant phenotype. NDRG1 
could be used as a potential diagnostic and prognostic marker for cervical cancer, as 
it is up-regulated in correlation with hypoxic status and might therefore play a role in 
treatment resistance. Whether NDRG1 over-expression in cervical cancer is 
associated with treatment outcome as a result of hypoxic induction remains to be 
further explored, and if so, silencing of NDRG1 expression in conjunction with 
radiotherapy and chemotherapy may prove to be a useful therapeutic strategy. In 
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summary, our study has highlighted the potential of NDRG1 as a promising anti-
cancer target in cervical carcinoma. 
 
 
5.4 Conclusion and future studies 
Our findings show that NDRG1 is consistently up-regulated in cervical tumours 
compared to non-tumourous and normal cervical tissue, strongly suggesting that 
NDRG1 plays a role in cervical carcinogenesis. This finding could be further 
extended by investigating the level of NDRG1 in cervical tumour tissue in relation to 
hypoxic status of these tissues, in order to determine if hypoxia is the reason behind 
up-regulation of NDRG1. To assess for NDRG1 up-regulation in cervical tumour 
tissues, immunohistochemical detection of NDRG1 can be performed on cervical 
tumour biopsies taken from cancer patients in whom tumour oxygenation 
measurements have been made. 
 
Functional studies using siRNA have revealed that down-regulation of NDRG1 leads 
to induction of a senescence-like phenotype; specifically, when NDRG1 is 
suppressed, cervical cancer cells undergo G1 cell cycle arrest and eventually cease 
to proliferate. Our data further show that induction of a senescence-like phenotype is 
mediated by the p53 pathway and p53 is required for the induction but not the 
maintenance of this senescence-like phenotype. Hence, up-regulation of NDRG1 
contributes to evasion of a senescence-like phenotype in cervical cancer cells, 
thereby playing a critical role in carcinogenesis.  Moreover, ectopic over-expression 
of NDRG1 leads to increased cell proliferation in SiHa cervical cancer cells, thereby 
suggesting that NDRG1 promotes tumour growth. However, further studies are 
needed to ascertain the pathways involved in NDRG1-mediated regulation of cell 
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growth and senescence, for example, it could be further explored if the p16/Rb 
pathway, which is abrogated in cervical cancer, plays a role in NDRG1-mediated 
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